# This Page Is Inserted by IFW Operations and is not a part of the Official Record

### BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION

	(51) International Passes Co. 15 11 5	<del></del>	PCT)		
(51) International Patent Classification 5:		(11) International Publication Number:	11/0 00/0/00		
	C12N 15/64, 15/70	Al	. tamber.	WO 92/06204	
			(43) International Publication Date:	16 April 1992 (16.04.92) :	
				(10.04.91)	
1	(21) International Application Numbers	DOT			

ternational Application Number:

(22) International Filing Date:

27 September 1991 (27.09.91)

(30) Priority data:

590,219

28 September 1990 (28.09.90) US

(71) Applicant: IXSYS, INC. [US/US]: 3550 General Atomics Court, Suite L103, San Diego, CA 92121 (US).

(72) Inventor: HUSE, William, D.; 471 Avenida Primavera, Del Mar, CA 92014 (US).

(74) Agents: CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).

PCT/US91/07149 (81) Designated States: AT (European patent), AU, BB. BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA. CF (OAPI patent), CG (OAPI patent). CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent). ES (European patent). FI, FR (European patent). GA (OAPI patent). GB (European patent). GN (OAPI patent). GR (European patent), HU, IT (European patent). tent), JP, KP, KR, LK, LU (European patent), MC, MG. ML (OAPI patent), MN. MR (OAPI patent), MW. NL (European patent), NO, PL. RO, SD, SE (European patent), SN (OAPI patent). SU\*,TD (OAPI patent). TG (OAPI patent).

Published

With international search report.

(54) Title: SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

#### (57) Abstract

A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heterometic receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

#### + DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain		
AU	Australia	FI	Finland	MG	Madagascar
88	Barbados	FR	France	ML	Mali
BΕ	Belgium	GA		MN	Mongolus .
BF	Burkina Fixo		Gahon	MR	Mauritania
BG	Bulgaria	CB	United Kingdom	MW	Malawi
BJ	Benin Benin	CN	Guinea	NL	Netherlands
BR		CR	Groece	NO	Norway
	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	luly	R	Romania
CF	Central African Republic	JP	Japan		
cc	Congo	KP	Democratic People's Republic	SD	Sudan
CH	Switzerland		of Korus	SE	Sweden
CI	Côte d'Ivoire	KR		SN	Senegai
СМ	Cameroun	Li	Republic of Korea	SU *	Soviet Union
CZ	Cricholovskii		Liechtenstein	TD	Chad
DE		LK	Sri لياميا	TC	Togo
DK	Germany	LU	Lusemhourk	US	United States of Ameri
UN	Durmine	40	* 1 · · · · · · · · · · · · · · · · · ·		2

متقنادت التكند

## SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

1

#### BACKGROUND OF THE INVENTION

This invention relates generally to recombinant expression of heteromeric receptors and, more particularly, to expression of such receptors on the surface of filamentous bacteriophage.

Antibodies are heteromeric receptors generated by a vertebrates organism's immune system which bind to an The molecules are composed of two heavy and two 10 antigen. light chains disulfide bonded together. Antibodies have the appearance of a "Y" - shaped structure and the antigen binding portion being located at the end of both short arms of the Y. The region on the heavy and light chain 15 polypeptides which corresponds to the antigen binding portion is known as variable region. The differences between antibodies within this region are primarily responsible for the variation in binding specificities between antibody molecules. The binding specificities are a composite of the antigen interactions with both heavy and 20 light chain polypeptides.

The immune system has the capability of generating an almost infinite number of different antibodies. Such a large diversity is generated primarily through recombination to form the variable regions of each chain and through differential pairing of heavy and light chains. The ability to mimic the natural immune system and generate antibodies that bind to any desired molecule is valuable because such antibodies can be used for diagnostic and therapeutic purposes.

desired molecule was accomplished only through manipulation of natural immune responses. Methods included classical immunization techniques of laboratory animals and monoclonal antibody production. Generation of monoclonal antibodies is laborious and time consuming. It involves a series of different techniques and is only performed on animal cells. Animal cells have relatively long generation times and require extra precautions to be taken compared to procaryotic cells to ensure viability of the cultures.

10 A method for the generation of a large repertoire of diverse antibody molecules in bacteria has been described, Huse et al., Science, 246, 1275-1281 (1989), which is herein incorporated by reference. The method uses the bacteriophage lambda as the vector. The lambda vector is a long, linear double-stranded DNA molecule. Production of antibodies using this vector involves the cloning of heavy and light chain populations of DNA sequences into separate vectors. The vectors are subsequently combined randomly to form a single vector which directs the coexpression of heavy and light chains to form antibody fragments. disadvantage to this method is that undesired combinations of vector portions are brought together when generating the coexpression vector. Although these undesired combinations do not produce viable phage, they do however, result in a significant loss of sequences from the population and, 25 therefore, a loss in diversity of the number of different combinations which can be obtained between heavy and light chains. Additionally, the size of the lambda phage gene is large compared to the genes that encode the antibody 30 segments. This makes the lambda system inherently more difficult to manipulate as compared to other available vector systems.

There thus exists a need for a method to generate diverse populations of heteromeric receptors which mimics the natural immune system, which is fast and efficient and

results in only desired combinations without loss of diversity. The present invention satisfies these needs and provides related advantages as well.

#### SUMMARY OF THE INVENTION

The invention relates to a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor, said heteromeric receptors being expressed on the surface of a cell, preferably one which produces filamentous bacteriophage, such as M13. Vectors, cloning systems and methods of making and screening the heteromeric receptors are also provided.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the two vectors 15 used for surface expression library construction from heavy and light chain libraries. M13IX30 (Figure 1A) is the vector used to clone the heavy chain sequences (open box). The single-headed arrow represents the Lac p/o expression sequences and the double-headed arrow represents the portion of M13IX30 which is to be combined with M13IX11. 20 The amber stop codon and relevant restriction sites are also shown. M13IX11 (Figure 1B) is the vector used to clone the light chain sequences (hatched box). Thick lines represent the pseudo-wild type ( gVIII) and wild type (gVIII) gene VIII sequences. The double-headed arrow 25 represents the portion of M13IX11 which is to be combined with M13IX30. Relevant restriction sites are also shown. Figure 1C shows the joining of vector population from heavy and light chain libraries to form the functional surface expression vector M13IXHL. Figure 1D shows the generation of a surface expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 1E) for surface expression and

screening of the library.

Figure 2 is the nucleotide sequence of M13IX30 (SEQ ID NO: 1).

Figure 3 is the nucleotide sequence of M13IX11 (SEQ ID 5 NO:2).

Figure 4 is the nucleotide sequence of M13IX34 (SEQ ID NO: 3) .

Figure 5 is the nucleotide sequence of M13IX13 (SEQ ID NO: 4).

Figure 6 is the nucleotide sequence of M13IX60 (SEQ ID NO: 5).

### DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to simple and efficient methods to generate a large repertoire of diverse 15 combinations of heteromeric receptors. The method is advantageous in that only proper combinations of vector portions are randomly brought together for the coexpressionof different DNA sequences without loss of population size or diversity. The receptors can be expressed on the 20 surface of cells, such as those producing filamentous bacteriophage, which can be screened in large numbers. nucleic acid sequences encoding the receptors be readily characterized because the filamentous bacteriophage produce single strand DNA for efficient sequencing and mutagenesis methods. The heteromeric receptors so produced are useful 25 in an unlimited number of diagnostic and therapeutic procedures.

In one embodiment, two populations of diverse heavy (Hc) and light (Lc) chain sequences are synthesized by

10

polymerase chain reaction (PCR). These populations are cloned into separate M13-based vector containing elements necessary for expression. The heavy chain vector contains a gene VIII (gVIII) coat protein sequence so that translation of the Hc sequences produces gVIII-Hc fusion proteins. The populations of two vectors are randomly combined such that only the vector portions containing the Hc and Lc sequences are joined into a single circular vector. The combined vector directs the coexpression of both Hc and Lc sequences for assembly of the two polypeptides and surface expression on M13. A mechanism also exists to control the expression of gVIII-Hc fusion proteins during library construction and screening.

As used herein, the term "heteromeric receptors" refers to proteins composed of two or more subunits which together exhibit binding activity toward particular molecule. It is understood that the term includes the subunit fragments so long as assembly of the polypeptides and function of the assembled complex is retained. Heteromeric subunits include, for example, antibodies and fragments thereof such as Fab and (Fab), portions, T cell receptors, integrins, hormone receptors and transmitter receptors.

As used herein, the term "preselected molecule" refers
to a molecule which is chosen from a number of choices.
The molecule can be, for example, a protein or peptide, or
an organic molecule such as a drug. Benzodiazapam is a
specific example of a preselected molecule.

As used herein, the term "coexpression" refers to the

expression of two or more nucleic acid sequences usually
expressed as separate polypeptides. For heteromeric
receptors, the coexpressed polypeptides assemble to form
the heteromer. Therefore, "expression elements" as used
herein, refers to sequences necessary for the

transcription, translation, regulation and sorting of the expressed polypeptides which make up the heteromeric receptors. The term also includes the expression of two subunit polypeptides which are linked but are able to assemble into a heteromeric receptor. A specific example of coexpression of linked polypeptides is where Hc and Lc polypeptides are expressed with a flexible peptide or polypeptide linker joining the two subunits into a single chain. The linker is flexible enough to allow association of Hc and Lc portions into a functional Fab fragment.

The invention provides for a composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

DNA sequences encoding the polypeptides heteromeric receptors are obtained by methods known to one skilled in the art. Such methods include, for example, 20 cDNA synthesis and polymerase chain reaction (PCR). need will determine which method or combinations of methods is to be used to obtain the desired populations of sequences. Expression can be performed in any compatible vector/host system. 25 Such systems include, for example, plasmids or phagemids in procaryotes such as E. coli, yeast systems and other eucaryotic systems such as mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the 30 surface of filamentous bacteriophage. Filamentous bacteriophage include, for example, M13, fl and Additionally, the heteromeric receptors can also expressed in soluble or secreted form depending on the need and the vector/host system employed.

Expression of heteromeric receptors such as antibodies or functional fragments thereof on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 1. Construction of the vectors enabling one of ordinary skill to make them are explicitly set out in Example I. The complete nucleotide sequences are given in Figures 2 and 3 (SEQ ID NOS: 1 and 2). This system produces randomly combined populations of heavy (Hc) and light (Lc) chain antibody fragments functionally linked to expression elements. The Hc polypeptide is produced as a fusion protein with the M13 coat protein encoded by gene The gVIII-Hc fusion protein therefore anchors the assembled Hc and Lc polypeptides on the surface of M13. The diversity of Hc and Lc combinations obtained by this system can be 5  $\times$  10 $^{7}$  or greater. Diversity of less than 5 . 15 x 107 can also be obtained and will be determined by the need and type of heteromeric receptor to be expressed.

Populations of Hc and Lc encoding sequences to be combined into a vector for coexpression are each cloned into separate vectors. For the vectors shown in Figure 1, 20 diverse populations of sequences encoding Hc polypeptides are cloned into M13IX30 (SEQ ID NO: 1). Sequences encoding Lc polypeptides are cloned into M13IX11 (SEQ ID NO: 2). The populations are inserted between the Xho I-Spe I or Stu I restriction enzyme sites in M13IX30 and between the Sac 25 I-Xba I or Eco RV sites in M13IX11 (Figures 1A and B, respectively).

The populations of Hc and Lc sequences inserted into the vectors can be synthesized with appropriate restriction recognition sequences flanking 30 opposite ends encoding sequences but this is not necessary. The sites allow annealing and ligation in-frame with expression elements of these sequences into a double-stranded vector restricted with the appropriate restriction enzyme. Alternatively, and a preferred embodiment, the Hc and Lc 35

15

35

organist Comments

sequences can be inserted into the vector restriction of the DNA. This method of cloning is beneficial because naturally encoded restriction enzyme sites may be present within the sequences, thus, causing destruction of the sequence when treated with a restriction enzyme. For cloning without restriction, the sequences are treated briefly with a 3' to 5' exonuclease such as T4 DNA polymerase or exonuclease III. A 5' to 3' exonuclease will also accomplish the same function. The protruding 5' termini which remains should be complementary to singl stranded overhangs within the vector which remain after restriction at the cloning site and treatment with exonuclease. The exonuclease treated inserts are annealed with the restricted vector by methods known to one skilled in the art. The exonuclease method decreases background and is easier to perform.

The vector used for Hc populations, Ml3IX30 (Figure 1A; SEQ ID NO: 1) contains, in addition to expression elements, a sequence encoding the pseudo-wild type gVIII product downstream and in frame with the cloning sites. 20 This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce homologous recombination with the wild type gVIII contained on the same vector. The wild type gVIII is: present to ensure that at least some functional, non-fusion 25 coat protein will be produced. The inclusion of a wild. type gVIII therefore reduces the possibility of non-viable phage production and biological selection against certain peptide fusion proteins. Differential regulation of the two genes can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the cloning sites is an amber stop codon. The stop codon is located between the inserted Hc sequences and the gVIII sequence and is in frame. As was the function of the wild

20

type gVIII, the amber stop codon also reduces biological selection when combining vector portions to produce functional surface expression vectors. This is: accomplished by using a non-suppressor (sup 0) host strain the non-suppressor strains will terminate expression after the Hc sequences but before the pseudo gVIII sequences. Therefore, the pseudo gVIII will essentially never be expressed on the phage surface under these circumstances. Instead, only soluble Hc polypeptides will be produced. Expression in a non-suppressor host strain can be advantageously utilized when one wishes to produce large populations of antibody fragments. codons other than amber, such as opal and ochre, or molecular switches, such as inducible repressor elements, can also be used to unlink peptide expression from surface expression.

The vector used for Lc populations, M13IX11 (SEQ ID NO: 2), contains necessary expression elements and cloning sites for the Lc sequences, Figure 1B. As with M13IX30, upstream and in frame with the cloning sites is a leader sequence for sorting to the phage surface. Additionally, a ribosome binding site and Lac Z promoter/operator elements are also present for transcription and translation of the DNA sequences.

Both vectors contain two pairs of Mlu I-Hind III 25 restriction enzyme sites (Figures 1A and B) for joining. together the Hc and Lc encoding sequences and their associated vector sequences. Mlu I and Hind III are noncompatible restriction sites. The two pairs symmetrically orientated about the cloning site so that 30 only the vector portions containing the sequences to be expressed are exactly combined into a single vector. The two pairs of sites are oriented identically with respect to one another on both vectors and the DNA between the two sites must be homologous enough between both vectors to 35

allow annealing. This orientation allows cleavage of each circular vector into two portions and combination of essential components within each vector into a single circular vector where the encoded polypeptides can be coexpressed (Figure 1C).

Any two pairs of restriction enzyme sites can be used so long as they are symmetrically orientated about the cloning site and identically orientated on both vectors. The sites within each pair, however, should be nonidentical or able to be made differentially recognized as a cleavage substrate. For example, the two pairs of restriction sites contained within the vectors shown in Figure 1 are Mlu I and Hind III. sites differentially cleavable by Mlu I and Hind III respectively. One skilled in the art knows how to substitute alternative pairs of restriction enzyme sites for the Mlu I-Hind III pairs described above. instead of two Hind III and two Mlu I sites, a Hind III and Not I site can be paired with a Mlu I and a Sal I site, for 20 example.

The combining step randomly brings together different HC and LC encoding sequences within the two diverse populations into a single vector (Figure 1C; M13IXHL). The vector sequences donated from each independent vector, M13IX30 and M13IX11, are necessary for production of viable phage. Also, since the pseudo gVIII sequences are contained in M13IX30, coexpression of functional antibody fragments as Lc associated gVIII-Hc fusion proteins cannot be accomplished on the phage surface until the vector sequences are linked as shown in M13IXHL.

The combining step is performed by restricting each population of Hc and Lc containing vectors with Mlu I and Hind III, respectively. The 3' termini of each restricted vector population is digested with a 3' to 5' exonuclease

as described above for inserting sequences into the cloning sites. The vector populations are mixed, allowed to anneal and introduced into an appropriate host. A non-suppressor host (Figure 1D) is preferably used during initial construction of the library to ensure that sequences are not selected against due to expression as fusion proteins. Phage isolated from the library constructed in a non-suppressor strain can be used to infect a suppressor strain for surface expression of antibody fragments.

10 method selecting a heteromeric for exhibiting binding activity toward a preselected morecule from a population of diverse heteromeric receptors, comprising: (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a 15 diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site; (b) operationally linking to second vector a second population of diverse DNA sequences encoding a diverse population of 20 said second vector having two pairs of polypeptides, restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and 25 second DNA sequences; (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and (e) determining the heteromeric receptors which bind to said preselected molecule. invention also provides for determining the nucleic acid sequences encoding such polypeptides as well.

Surface expression of the antibody library is performed in an amber suppressor strain. As described above, the amber stop codon between the Hc sequence and the

gVIII sequence unlinks the two components in a nonsuppressor strain. Isolating the phage produced from the non-suppressor strain and infecting a suppressor strain will link the Hc sequences to the gVIII sequence during expression (Figure 1E). Culturing the suppressor strain after infection allows the coexpression on the surface of M13 of all antibody species within the library as gVIII fusion proteins (gVIII-Fab fusion proteins). Alternatively, the DNA can be isolated from the nonsuppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of gVIII-Fab fusion proteins can additionally be controlled at the transcriptional level. Both polypeptides of the gVIII-Fab fusion proteins 15 under the inducible control of the promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. high levels of surface expression, the suppressor library is cultured in an inducer of the Lac Z promoter such as isopropylthio-B-galactoside (IPTG). -20 Inducible control is beneficial because biological selection against nonfunctional gVIII-Fab fusion proteins can be minimized by culturing the library under non-expressing conditions. Expression can then be induced only at the time of. screening to ensure that the entire population antibodies within the library are accurately represented on the phage surface. Also, this can be used to control the valency of the antibody on the phage surface.

The surface expression library is screened for specific Fab fragments which bind preselected molecules by standard affinity isolation procedures. Such methods include, for example, panning, affinity chromatography and solid phase blotting procedures. Panning as described by Parmley and Smith, Gene 73:305-318 (1988), which is incorporated herein by reference, is preferred because high

titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select minor Fab fragments species within the population, which otherwise would have been undetectable, and amplified to substantially homogenous populations. The selected Fab fragments can be characterized by sequencing the nucleic acids encoding the polypeptides after amplification of the phage population.

The following examples are intended to illustrate but 10 not limit the invention.

#### EXAMPLE I

# Construction, Expression and Screening of Antibody Fragments on the Surface of M13

This example shows the synthesis of a diverse population of heavy (Hc) and light (Lc) chain antibody fragments and their expression on the surface of M13 as gene VIII-Fab fusion proteins. The expressed antibodies derive from the random mixing and coexpression of a Hc and Lc pair. Also demonstrated is the isolation and characterization of the expressed Fab fragments which bind benzodiazapam (BDP) and their corresponding nucleotide sequence.

## Isolation of mRNA and PCR Amplification of Antibody Fragments

The surface expression library is constructed from mRNA isolated from a mouse that had been immunized with KLH-coupled benzodiazapam (BDP). BDP was coupled to keyhole limpet hemocyanin (KLH) using the techniques described in <a href="#">Antibodies: A Laboratory Manual</a>, Harlow and Lane, eds., Cold Spring Harbor, New York (1988), which is incorporated herein by reference. Briefly, 10.0 milligrams (mg) of keyhole limpet hemocyanin and 0.5 mg of BDP with a

glutaryl spacer arm N-hydroxysuccinimide linker appendages. Coupling was performed as in Jonda et al., <u>Science</u>, 241:1188 (1988), which is incorporated herein by reference. The KLH-BDP conjugate was removed by gel filtration chromatography through Sephadex G-25.

The KLH-BDP conjugate was prepared for injection into mice by adding 100  $\mu g$  of the conjugate to 250  $\mu l$  of phosphate buffered saline (PBS). An equal volume of complete Freund's adjuvant was added and emulsified the entire solution for 5 minutes. Mice were injected with 300 10  $\mu$ l of the emulsion. Injections were given subcutaneously at several sites using a 21 gauge needle. A second immunization with BDP was given two weeks later. injection was prepared as follows: 50  $\mu$ g of BDP was diluted in 250  $\mu$ l of PBS and an equal volume of alum was 15 mixed with the solution. The mice were injected intraperitoneally with 500  $\mu l$  of the solution using a 23 gauge needle. One month later the mice were given a final injection of 50  $\mu g$  of the conjugate diluted to 200  $\mu l$  in PBS. This injection was given intravenously in the lateral 20 tail vein using a 30 gauge needle. Five days after this final injection the mice were sacrificed and total cellular RNA was isolated from their spleens.

Total RNA was isolated from the spleen of a single mouse immunized as described above by the method of Chomczynski and Sacchi, Anal. Biochem., 162:156-159 (1987), which is incorporated herein by reference. immediately after removing the spleen from the immunized mouse, the tissue was homogenized in 10 ml of a denaturing solution containing 4.0 M guanine isothiocyanate, 0.25 M 30 sodium citrate at pH 7.0, and 0.1 M 2-mercaptoethanol using a glass homogenizer. One ml of sodium acetate at a concentration of 2 M at pH 4.0 was mixed with the homogenized spleen. One ml of saturated phenol was also mixed with the denaturing solution containing 35

homogenized spleen. Two ml of a chloroform:isoamyl alcohol (24:1 v/v) mixture was added to this homogenate. homogenat was mixed vigorously for ten seconds and maintained on ice for 15 minutes. The homogenate was then 5 transferred to a thick-walled 50 ml polypropylene centrifuge tube (Fisher Scientific Company, Pittsburgh, PA). The solution was centrifuged at 10,000 x g for 20 minutes at 4°C. The upper RNA-containing aqueous layer was transferred to a fresh 50 ml polypropylene centrifuge tube and mixed with an equal volume of isopropyl alcohol. This 10 solution was maintained at -20°C for at least one hour to precipitate the RNA. The solution containing the precipitated RNA was centrifuged at 10,000 x g for twenty minutes at 4°C. The pelleted total cellular RNA was 15 collected and dissolved in 3 ml of the denaturing solution described above. Three mls of isopropyl alcohol was added to the resuspended total cellular RNA and vigorously mixed. This solution was maintained at -20°C for at least 1 hour to precipitate the RNA. The solution containing the precipitated RNA was centrifuged at 10,000 x g for ten 20 minutes at 4°C. The pelleted RNA was washed once with a solution containing 75% ethanol. The pelleted RNA was dried under vacuum for 15 minutes and then resuspended in dimethyl pyrocarbonate (DEPC) treated (DEPC-H2O) H2O.

Poly A RNA for use in first strand cDNA synthesis was prepared from the above isolated total RNA using a spin-column kit (Pharmacia, Piscataway, NJ) as recommended by the manufacturer. The basic methodology has been described by Aviv and Leder, Proc. Natl. Acad. Sci., USA, 69:1408-1412 (1972), which is incorporated herein by reference. Briefly, one half of the total RNA isolated from a single immunized mouse spleen prepared as described above was resuspended in one ml of DEPC-treated dH<sub>2</sub>O and maintained at 65°C for five minutes. One ml of 2x high salt loading buffer (100 mM Tris-HCL at pH 7.5, 1 M sodium chloride, 2.0 mM disodium ethylene diamine tetraacetic acid (EDTA) at pH

عجائلتها بالمناد والراارة

8.0, and 0.2% sodium dodecyl sulfate (SDS)) was added to the resuspended RNA and the mixture was allowed to cool to room temperature. The mixture was then applied to an oligo-dT (Collaborative Research Type 2 or Type 3 Bedford, MA) column that was previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and then equilibrating the column with DEPCtreated dH,o. The eluate was collected in a sterile polypropylene tube and reapplied to the same column after heating the eluate for 5 minutes at 65°C. The oligo dT column was then washed with 2 ml of high salt loading buffer consisting of 50 mM Tris-HCL at pH 7.5, 500 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS. oligo dT column was then washed with 2 ml of 1 X medium salt buffer (50 mM Tris-HCL at pH 7.5, 100 mM sodium 15 chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS). The mRNA was eluted with 1 ml of buffer consisting of 10 mm Tris-HCL atpH 7.5, 1 mM EDTA at pH 8.0 and 0.05% SDS. The messenger RNA was purified by extracting this solution with phenol/chloroform followed by a single extraction with 100% 20 chloroform, ethanol precipitated and resuspended in DEPC treated dH,o.

In preparation for PCR amplification, mRNA was used as a template for cDNA synthesis. In a typical 250 µl reverse transcription reaction mixture, 5-10 µg of spleen mRNA in water was first annealed with 500 ng (0.5 pmol) of either the 3' V<sub>k</sub> primer (primer 12, Table I) or the 3' V<sub>l</sub> primer (primer 9, Table II) at 65°C for 5 minutes. Subsequently, the mixture was adjusted to contain 0.8 mM dATP, 0.8 mM dCTP, 0.8 mM dCTP, 0.8 mM dTTP, 100 mM Tris-HCL (pH 8.6), 10 mM MgCl<sub>2</sub>, 40 mM KCl, and 20 mM 2-ME. Moloney-Murine Leukemia Virus (Bethesda Research Laboratories (BRL), Gaithersburg, MD) Reverse transcriptase, 26 units, was added and the solution was incubated for 1 hour at 40°C.

The resultant first strand cDNA was phenol extracted, ethanol precipitated and then used in the polymerase chain

reaction (PCR) procedures described below for amplification of heavy and light chain sequences.

Primers used for amplification of heavy chain Fd fragments for construction of the M13IX30 library is shown 5 in Table I. Amplification was performed in eight separate reactions, as described by Saiki et al., Science, 239:487-491 (1988), which is incorporated herein by reference, each reaction containing one of the 5' primers (primers 2 to 9; SEQ ID NOS: 7 through 14, respectively) and one of the 3' primers (primer 12; SEQ ID NO: 17) listed in Table I. 10 remaining 5' primers, used for amplification in a single reaction, are either a degenerate primer (primer 1; SEQ ID NO: 6) or a primer that incorporates inosine at four degenerate positions (primer 10; SEQ ID NO: 15). remaining 3' primer (primer 11; SEQ ID NO: 16) was used to. 15 construct Fv fragments. The underlined portion of the 5' primers incorporates an Xho I site and that of the 3' primer an Spe I restriction site for cloning the amplified fragments into the M13IX30 vector in a predetermined reading frame for expression.

#### TABLE I HEAVY CHAIN PRIMERS

1) 5'- AGGT A CT CTCGAGTC GG - 3' 25 5' - AGGTCCAGCTGCTCGAGTCTGG - 3' 2) 5' - AGGTCCAGCTGCTCGAGTCAGG - 3' 3) 5' - AGGTCCAGCTTCTCGAGTCTGG - 3' 4) 5' - AGGTCCAGCTTCTCGAGTCAGG - 3' 5) 30 5' - AGGTCCAACTGCTCGAGTCTGG - 3' 6) 5' - AGGTCCAACTGCTCGAGTCAGG - 3' 7) 5' - AGGTCCAACTTCTCGAGTCTGG - 3' 8)

- 9) 5' AGGTCCAACTTCTCGAGTCAGG 3'
- 10) 5' AGGTIIAICTICTCGAGTC GG 3'
- 5 11) 5' CTATTA<u>ACTAGT</u>AACGGTAACAGT GGTGCCTTGCCCCA 3'
  - 12) 5' AGGCTT<u>ACTAGT</u>ACAATCCCTGG GCACAAT 3'

Primers used for amplification of mouse kappa light chain sequences for construction of the M13IX11 library are 10 shown in Table II. These primers were chosen to contain restriction sites which were compatible with vector and not present in the conserved sequences of the mouse light chain Amplification was performed as described above in mRNA. five separate reactions, each containing one of the 5' primers (primers 3 to 7; SEQ ID NOS: 20 through 24, respectively) and one of the 3' primers (primer 9; SEQ ID NO: 26) listed in Table II. The remaining 3' primer (primer 8; SEQ ID NO: 25) was used to construct Fv 20 The underlined portion of the 5' primers depicts a Sac I restriction site and that of the 3' primers an Xba I restriction site for cloning of the amplified fragments into the M13IX11 vector in a predetermined reading frame for expression.

# 25 TABLE II LIGHT CHAIN PRIMERS

- 1) 5' CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT 3'
- 2) 5' CCAGTTCCGAGCTCGTGTTGACGCAGCCGCCC 3'
- 3) 5' CCAGTTCCGAGCTCGTGCTCACCCAGTCTCCA 3'
- 30 4) 5' CCAGTTCCGAGCTCCAGATGACCCAGTCTCCA 3'
  - 5) 5' CCAGATGTGAGCTCGTGATGACCCAGACTCCA 3'
  - 6) 5' CCAGATGTGAGCTCGTCATGACCCAGTCTCCA 3'
  - 7) 5' CCAGTTCCGAGCTCGTGATGACACAGTCTCCA 3'
  - 8) 5' GCAGCAT<u>TCTAGAGTTTCAGCTCCAGCTTGCC 3'</u>
- 9) 5' GCGCCG<u>TCTAGA</u>ATTAACACTCATTCCTGTTGAA 3'

PCR amplification for heavy and light chain fragments was performed in a 100  $\mu$ l reaction mixture containing the above described products of the reverse transcription reaction ( $\approx$ 5 $\mu$ g of the cDNA-RNA hybrid), 300 nmol of 3'  $V_{_{\rm H}}$ primer (primer 12, Table I; SEQ ID NO: 17), and one of the 5' V<sub>H</sub> primers (primers 2-9, Table I; SEQ ID NOS: 7 through 14, respectively) for heavy chain amplification, or, 300 nmol of 3' V<sub>l</sub> primer (primer 9, Table II; SEQ ID NO: 26), and one of the 5' V primers (primers 3-7, Table II; SEQ ID NOS: 20 through 24, respectively) for each light chain 10 amplification, a mixture of dNTPs at 200 mM, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl<sub>2</sub>, 0.1% gelatin, and 2 units of Thermus aquaticus DNA polymerase. The reaction mixture was overlaid with mineral oil and subjected to 40 cycles of 15 amplification. Each amplification cycle denaturation at 92°C for 1 minute, annealing at 52°C for 2 involved minutes, and elongation at 72°C for 1.5 minutes. amplified samples were extracted twice with phenol/CHCl3 and once with CHCl<sub>3</sub>, ethanol-precipitated, and stored at -70°C in 10 mm Tris-HCl, pH 7.5 1 mM EDTA. 20 The resultant products were used in constructing the M13IX30 and M13IX11 libraries (see below).

#### <u>Vector Construction</u>

- Two M13-based vectors, M13IX30 (SEQ ID NO: 1) and 25 M13IX11 (SEQ ID NO: 2), were constructed for the cloning and propagation of Hc and Lc populations of antibody fragments, respectively. The vectors were constructed to facilitate the random joining and subsequent surface expression of antibody fragment populations.
- M13IX30 (SEQ ID NO: 1), or the Hc vector, was constructed to harbor diverse populations of Hc antibody fragments. M13mp19 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene VIII: (1) a

WO 92/06204

pseudo-wild type gene VIII sequence with an amber stop codon between it and the restriction sites for cloning oligonucleotides; (2) Stu I restriction site for insertion of sequences by hybridization and, Spe I and Xho I restriction sites in-frame with the pseudo-wild type gene VIII for cloning Hc sequences; (3) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (4) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (5) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

Construction of M13IX30 was performed in four steps. In the first step, an M13-based vector containing the pseudo gVIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield M13IX03. This vector was then expanded to contain expression sequences and restriction sites for Hc sequences to form M13IX04B. The fourth and final step involved the incorporation of the newly constructed sequences in M13IX04B into M13IX01F to yield M13IX30.

Construction of M13IXO1F first involved the generation of a pseudo wild-type gVIII sequence for surface expression of antibody fragments. The pseudo-wild type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene

attanta Talanta

VIII facilitates the growth of phage under conditions where there is surface expression of the polypeptides and therefore reduces the possibility of non-viable phage production from the fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table III.

22

TABLE III

## Pseudo-Wild Type Gene VIII Oligonucleotide Series

	Top Strand Oligonucleotides	Sequence (5' to 3')
5	VIII 03	GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT
3.0	VIII 04	GC A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAC
10	VIII 05	A TT GGC TAC GCT TGG GCT
	VIII 06	ATG GTA GTA GTT ATA GTT GGT GCT ACC ATA GGG ATT
15	VIII 07	AAA TTA TTC AAA AAG TT T ACG AGC AAG GCT TCT TA
	Bottom Strand Oligonucleotides	
20	VIII OB	AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA
	VIII 09	TTT AAT CCC TAT GGT AGC ACC
25	VIII 10	AAC TAT AAC TAC TAC CAT AGC CCA AGC GTA GCC AAT
	VIII 11	GTA CTC AGT AGC ACT TG C CTG TAA ACT ATT GAA
	VIII 12	TGC AGC CTT AGC AGG GTC ATC GCC TTC AGC CTA G

Except for the terminal oligonucleotides VIII 03 (SEQ 30 ID NO: 27) and VIII 08 (SEQ ID NO: 32), the above oligonucleotides (oligonucleotides VIII 04-07 (SEQ ID NOS: 28 through 31, respectively) and VIII 09-12 (SEQ ID NOS: 33

through 36, respectively)) were mixed at 200 ng each in 10  $\mu$ l final volume, phosphorylated with T4 polynucleotide Kinase (Pharmacia) and 1 mM ATP at 37°C for 1 hour, heated to 70°C for 5 minutes, and annealed into double-stranded form by heating to 65°C for 3 minutes, followed by cooling to room temperature over a period of 30 minutes. reactions were treated with 1.0 U of T4 DNA ligase (BRL) and 1 mM ATP at room temperature for 1 hour, followed by heating to 70°C for 5 minutes. Terminal oligonucleotides were then annealed to the ligated oligonucleotides. 10 annealed and ligated oligonucleotides yielded a doublestranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII sequence begins with the codon GAA (Glu) two codons 3' to 15 the stop codon. The double-stranded insert was cloned in frame with the Eco RI and Sac I sites within the M13 polylinker. To do so, M13mp19 was digested with Bam HI. (New England Biolabs, Beverley, MA) and Hind III (New England Biolabs) and combined at a molar ratio of 1:10 with 20 the double-stranded insert. The ligations were performed at room temperature overnight in 1% ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl<sub>2</sub>, 20 mM DTT, 1 mM ATP, 50  $\mu$ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England 25 Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the construct to yield functional M13I.01F. The mutations were generated using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was performed as recommended by the manufacturer.

Two Fok I sites were removed from the vector as well as the Hind III site at the end of the pseudo gene VIII using the oligonucleotides mutant CATTTTTGCAGATGGCTTAGA-3 (SEQ ID NO: 37) and TAGCATTAACGTCCAATA-3' (SEQ ID NO: 38). New Hind III and Mlu I sites were also introduced at position 3919 and 3951 of M13IXO1F. The oligonucleotides used for mutagenesis had the sequences 5 1 -ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 39) and 51-10 GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 40), respectively. The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the mutant oligonucleotide 5'-GCGGGCCTCTTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 41). In constructing the above mutations, all 15 changes made in a M13 coding region were performed such that the amino acid sequence remained unaltered. resultant vector, M13IX01F, was used in the final step to construct M13IX30 (see below).

In the second step, M13mp18 was mutated to remove the 5' end of Lac Z up to the Lac i binding site and including 20 the Lac ribosome binding site and start Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. A single oligonucleotide was used for these mutagenesis and had the sequence 5'-AAACGACGGCCAGTGCCAAGTGACGCGTGTGAAATTGTTATCC-3' 25 (SEQ ID NO: 42). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the Mlu I site using the oligonucleotide 5'-GGCGAAAGGGAATTCTGCAAGGCGATTAAGCTTGGG TAACGCC-3' (SEQ ID NO. 43). These modifications of M13mp18 yielded the precursor vector M13IX03. 30

The expression sequences and cloning sites were introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table IV.

TABLE IV
M13IX30 Oligonucleotide Series

	Top Strand Oligonucleotides	Sequence (5' to 3')
5	084	GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT
	028	TACTGTTTACCCCTGTGACAAAAGCCGCCCAGGTCC AGCTGC
10	029	TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG
	Bottom Oligonucleotides	Sequence (5' to 3')
	085	TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG
15	5 031	GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT
	032	TTGTCACAGGGGTAAACAGTAACGGTAACGGTAAGTGT GCCA
20	033	GTGCAATAGTGCTTTGTTTCACTTTATTTTCTCCATGT ACAA

The above oligonucleotides of Table IV, except for the terminal oligonucleotides 084 (SEQ ID NO: 44) and 085 (SEQ ID NO: 48), were mixed, phosphorylated, annealed and ligated to form a double-stranded insert as described in-Example I. However, instead of cloning directly into the intermediate vector the insert was first amplified by PCR. The terminal oligonucleotides were used as primers for PCR. Oligonucleotide 084 (SEQ ID NO: 44) contains a Hind III site, nucleotides internal to its 5 ' 30 oligonucleotide 085 (SEQ ID NO: 48) has an Eco RI site atits 5' end. Following amplification, the products were restricted with Hind III and Eco RI and ligated, as described in Example I, into the polylinker of M13mp18 digested with the same two enzymes. The resultant double

stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The intermediate vector was named M13IX04.

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is missing one of the two GCC codons. 10 Additionally, oligonucleotide 032 (SEQ ID NO: 50) contained a GTG codon where a GAG codon was needed. Mutagenesis Was performed using oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 52) to convert the codon to the desired sequence. resultant vector is named M13IX04B. 15

The third step in constructing M13IX30 involved inserting the expression and cloning sequences from M13IX04B upstream of the pseudo wild-type gVIII M13IX01F. This was accomplished by digesting M13IX04B with Dra III and Bam HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 1:1 and ligated as described in Example I. The sequence 25 of the final construct M13IX30, is shown in Figure 2 (SEQ ID NO: 1). Figure 1A also shows M13IX30 where each of the elements necessary for surface expression of Hc fragments is marked. It should be noted during modification of the vectors, certain sequences differed from the published sequence of M13mp18. The new sequences are incorporated into the sequences recorded herein.

M13IX11 (SEQ ID NO: 2), or the Lc vector, was constructed to harbor diverse populations of Lc antibody fragments. This vector was also constructed from M13mp19

and contains: (1) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (2) Eco RV restriction site for insertion of sequences by hybridization and Sac I and Xba I restriction sites for cloning of Lc sequences; (3) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (4) various other mutation to remove redundant restriction sites.

expression, translation initiation signals, cloning sites, and one of the Mlu I sites were constructed 10 by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table V and were ligated as a double-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the expression sequences inserted into M13IX03. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 55). 20

TABLE V

### Oligonucleotide Series for Construction of Translation Signals in M13IX11

	<u>Oligonucleotide</u>	Sequence (5' to 3')
5	082	CACC TTCATG AATTC GGC AAG GAGACA GTCAT
	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG
10	017	GCA GCC GCT GGA TTG TT ATTA CTC GCT GCC CAA CCA GCC ATG GCC GAG CTC GTG AT
	018	GACC CAG ACT CCA GATATC CAA
15	019 083	CAG GAA TGA GTG TTA AT TCT AGA ACG CGT C TTCAGGTTGAAGC TTA CGC GTT
		CTA GAA TTA ACA CTC ATT
	021	TG GAT ATC TGG AGT CTG GGT CAT CAC GAG CTC GGC CAT G
20	022	GC TGG TTG GGC AGC GAG TAA
	023	TAA CAA TCC AGC GGC TGC C GT AGG CAA TAG GTA TTT CAT TAT GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 56) contained a Sac I restriction site 67 nucleotides downstream from the ATG codon. The naturally occurring Eco RI site was removed and new Eco RI and Hind III sites were introduced downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 63) and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 64) were used to generate each of the mutations, respectively. The Lac Z ribosome binding site was removed when the

วิทยาและ และเหมือน

original Eco RI site in M13mp19 was mutated. Additionally, when the new Eco RI and Hind III sites were generated, a spontaneous 100 bp deletion was found just 3' to these sites. Since the deletion does not affect the function, it was retained in the final vector.

In addition to the above mutations, a variety of other modifications were made to incorporate or remove certain sequences. The Hind III site used to ligate the doubl - stranded insert was removed with the oligonucleotide 5'-10 GCCAGTGCCAAGTGACGCGTTCTA-3' (SEQ ID NO: 65). Second Hind III and Mlu I sites were introduced at positions 3922 and 3952, respectively, using the oligonucleotides 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 66) for the Hind III mutagenesis and 5'-GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 67) for the Mlu I mutagenesis. Again, mutations within the coding region did not alter the amino acid sequence.

The sequence of the resultant vector, M13IX11, is shown in Figure 3 (SEQ ID NO: 2). Figure 1B also shows M13IX11 where each of the elements necessary for producing a surface expression library between Lc fragments is marked.

### Library Construction

Each population of Hc and Lc sequences synthesized by PCR above are separately cloned into M13IX30 and M13IX11, respectively, to create Hc and Lc libraries.

The Hc and Lc products (5 µg) are mixed, ethanol precipitated and resuspended in 20 µl of NaOAc buffer (33 mM Tris acetate, pH 7.9, 10 mM Mg-acetate, 66 mM K-acetate, 0.5 mM DTT). Five units of T4 DNA polymerase is added and the reactions incubated at 30°C for 5 minutes to remove 3' termini by exonuclease digestion. Reactions are stopped by heating at 70°C for 5 minutes. M13IX30 is digested with

Stu I and M13IX11 is digested with Eco RV. Both vectors are treated with T4 DNA polymerase as described above and combined with the appropriate PCR products at a 1:1 molar ratio at 10 ng/µl to anneal in the above buffer at room temperature overnight. DNA from each annealing is electroporated into MK30-3 (Boehringer, Indianapolis, IN), as described below, to generate the Hc and Lc libraries.

E. coli MK30-3 is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cells are prepared by inoculating a fresh colony of MK30-3 into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0:186 g KCl, dH2O to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture 15 and grown with vigorous aeration at 37°C until the  $OD_{550}$  is 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm  $(2,600 \times g)$  in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended 20 ml of ice-cold 10% (v/v)in 500 sterile glycerol, centrifuged and resuspended a second time in the same manner. After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the  $OD_{550}$  of the suspension was 200 to 300. Usually, resuspension is achieved in the 10% glycerol 25 that remained in the bottle after pouring off the supernate. Cells are frozen in 40  $\mu$ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40  $\mu$ l of cell suspension. A 40  $\mu$ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 4 kN parallel resistor 25  $\mu$ F, 1.88 KV, which gives a pulse length ( $\tau$ ) of

 $^{-4}$  ms. A 10  $\mu$ l aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl, and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

Each of the libraries are cultured using methods known to one skilled in the art. Such methods can be found in Sanbrook et al., Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml library cultures are grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria ar pelleted by centrifugation at 10,000 x g. The supernatant containing phage is transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing Hc and Lc antibody fragments are isolated from the cell pellet of each 20 library. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 mg/ $\mu$ l lysozyne is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% is added followed by 10 minutes on ice. suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are centrifuged at 15,000 rpm for 15 minutes at 4°C, RNased and 30 extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of CsCl, is dissolved into each tube until a density of 1.60 g/ml is achieved. EtBr is added to 600 35 the double-stranded μq/ml and DNA is isolated by

equilibrium centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half sublibrary are used to generate forty libraries in which the right and left halves of the randomized oligonucleotides have been randomly joined together.

The surface expression library is formed by the random joining of the Hc containing portion of M13IX30 with the Lc containing portion of M13IX11. The DNAs isolated from each library was digested separately with an excess amount of 10 restriction enzyme. The Lc population (5  $\mu$ g) is digested with Hind III. The Hc (5  $\mu$ g) population is digested with The reactions are stopped by phenol/chloroform extraction followed by ethanol precipitation. The pellets are washed in 70% ethanol and resuspended in 20  $\mu l$  of NaOAc buffer. Five units of T4 DNA polymerase (Pharmacia) is added and the reactions incubated at 30°C for 5 minutes. Reactions are stopped by heating at 70°C for 5 minutes. The Hc and Lc DNAs are mixed to a final concentration of 10 ng each vector/ $\mu$ l and allowed to anneal at room temperature overnight. The mixture is electroporated into MK30-3 cells 20 as described above.

## Screening of Surface Expression Libraries

Purified phage are prepared from 50 ml liquid cultures of XL1 Blue<sup>TM</sup> cells (Stratagene, La Jolla, CA) which had been infected at a m.o.i. of 10 from the phage stocks stored at 4°C. The cultures are induced with 2 mM IPTG. Supernatants are cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. Phage pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly at room temperature for 30 minutes. The solutions are adjusted to

0.5 M NaCl and to a final concentration of 5% polyethylene glycol. After 2 hours at 4°C, the precipitates containing the phage ar recovered by centrifugation for 1 hour at: 15,000 X g. The precipitates are resuspended in 10 ml of 5 NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, mixed well, and the phage repelleted centrifugation at 170,000 X g for 3 hours. The phage pellets are resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at: 110,000 X g (3.86 g of cesium chloride in 10 ml of buffer). 10 Phage bands are collected, diluted 7-hold with NET buffer, recentrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

The BDP used for panning on streptavidin coated dishes: 15 is first biotinylated and then absorbed against UVinactivated blocking phage (see below). The biotinylating: reagents are dissolved in dimethylformamide at a ratio of solid NHS-SS-Biotin (sulfosuccinimidy) (biotinamido) ethyl-1,3'-dithiopropionate; Pierce, Rockford, 20 IL) to 1 ml solvent and used as recommended by the manufacturer. Small-scale reactions are accomplished by mixing 1  $\mu$ l dissolved reagent with 43  $\mu$ l of 1 mg/ml BDP: diluted in sterile bicarbonate buffer (0.1 M NaHCO3, pH 25 8.6). After 2 hours at 25°C, residual biotinylating. reagent is reacted with 500  $\mu$ l 1 M ethanolamine (pH) adjusted to 9 with HCl) for an additional 2 hours. entire sample is diluted with 1 ml TBS containing 1 mg/ml. BSA, concentrated to about 50  $\mu$ l on a Centricon 30 ultrafilter (Amicon), and washed on the same filter three times 30 with 2 ml TBS and once with 1 ml TBS containing 0.02% NaN3 and 7 x  $10^{12}$  UV-inactivated blocking phage (s e below); the final retentate (60-80  $\mu$ l) is stored at 4 °C. BDP biotinylated with the NHS-SS-Biotin reagent is linked to 35 biotin via a disulfide-containing chain.

UV-irradiated M13 phage are used for blocking any biotinylated BDP which fortuitously binds filamentous phage in general. M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) is chosen because it carries two amber mutations, which ensure that the few phage surviving irradiation will not grow in the sup O strains used to titer the surface expression library. A 5 ml sample containing 5 x 10<sup>13</sup> M13mp8 phage, purified as described above, is placed in a small petri plate and irradiated with a germicidal lamp at a distance of two feet for 7 minutes (flux 150 μW/cm²). NaN<sub>3</sub> is added to 0.02% and phage particles concentrated to 10<sup>14</sup> particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

For panning, polystyrene petri plates (60 x 15 mm) are incubated with 1 ml of 1 mg/ml of streptavidin (BRL) in 0.1 M NaHCO<sub>3</sub> pH 8.6-0.02% NaN<sub>3</sub> in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3 µg/ml of streptavidin; 0.1 M NaHCO<sub>3</sub> pH 8.6-0.02% NaN<sub>3</sub>) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing antibody fragments which bind BDP is performed with 5 μl (2.7 μg BDP) of blocked biotinylated BDP reacted with a 50 μl portion of the library. Each mixture is incubated overnight at 4°C, diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described above. After rocking 10 minutes at room temperature, unbound phage are removed and plates washed ten times with TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800 μl sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with glycerol) for 15 minutes and eluates neutralized with 48 μl

2 M Tris (pH unadjusted). A 20  $\mu l$  portion of each eluate is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750 5  $\mu$ l of first eluate from the library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated to a final volume of about 50  $\mu$ l. Final retentate is 10 transferred to a tube containing 5.0  $\mu$ l (2.7  $\mu$ g BDP) blocked biotinylated BDP and incubated overnight. solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated petri plates. The entire second eluate (800  $\mu$ l) neutralized with 48  $\mu$ l 2 M Tris, and 20  $\mu$ l is titered simultaneously with the first eluate and dilutions of the input phage. If necessary, further rounds of panning can be performed to obtain homogeneous populations of phage. Additionally, phage can be plaque purified if reagents are available for detection.

## Template Preparation and Sequencing

Templates are prepared for sequencing by inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque from the purified population. The plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then transferred to a 1.5 ml microfuge tube. 200 \(mu\)1 of PEG solution is added, followed by vortexing and placed on ice for 10 minutes. The phage precipitate is recovered by centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended in 230 \(mu\)1 of TE (10 mM Tris-HC1, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow

pipet tip. Phenol (200 μl) is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to a separate tube and extracted with 200 μl of phenol/chloroform (1:1) as described above for the phenol extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipated at -20°C for 20 minutes. The precipated templates are recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried and resuspended in 25 μl TE. Sequencing was performed using a Sequenase sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

#### EXAMPLE II

## Cloning of Heavy and Light Chain Sequences Without Restriction Enzyme Digestion

This example shows the simultaneous incorporation of antibody heavy and light chain fragment encoding sequences into a M13IXHL-type vector with the use of restriction endonucleases.

For the simultaneous incorporation of heavy and light chain encoding sequences into a single coexpression vector, a M13IXHL vector was produced that contained heavy and light chain encoding sequences for a mouse monoclonal antibody (DAN-18H4; Biosite, San Diego, CA). The inserted antibody fragment sequences are used as complementary sequences for the hybridization and incorporation of Hc and Lc sequences by site-directed mutagenesis. The genes encoding the heavy and light chain polypeptides were inserted into M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), respectively, and combined into a single surface expression vector as described in Example I. The resultant M13IXHL-type vector is termed M13IX50.

The combinations were performed under conditions that facilitate the formation of one Hc and one Lc vector half into a single circularized vector. Briefly, the overhangs generated between the pairs of restriction sites after restriction with Mlu I or Hind III and exonuclease digestion are unequal (i.e., 64 nucleotides compared to 32) nucleotides). These unequal lengths result in differential hybridization temperatures for specific annealing of the complementary ends from each vector. The specific. 10 hybridization of each end of each vector half accomplished by first annealing at 65°C in a small volume (about 100  $\mu$ g/ $\mu$ l) to form a dimer of one Hc vector half and one Lc vector half. The dimers were circularized by diluting the mixture (to about 20  $\mu g/\mu l$ ) and lowering the 15 temperature to about 25-37°C to allow annealing. T4 ligas . was present to covalently close the circular vectors.

M13IX50 was modified such that it did not produce as functional polypeptide for the DAN monoclonal antibody. To. do this, about eight amino acids were changed within the variable region of each chain by mutagenesis. 20 variable region was mutagenized using the oligonucleotide 5 '-CTGAACCTGTCTGGGACCACAGTTGATGCTATAGGATCAGATCTAGAATTCATT" TAGAGACTGGCCTGGCTTCTGC-3' (SEQ ID NO: 68). The Hc sequence: mutagenized with the oligonucleotide TCGACCGTTGGTAGGAATAATGCAATTAATG; 25 GAGTAGCTCTAAATTCAGAATTCATCTACACCCAGTGCATCCAGTAGCT-3 An additional mutation was also introduced ID NO: 69). into M13IX50 to yield the final form of the vector. construction of an intermediate to M13IX50 (M13IX04 described in Example I), a six nucleotide sequence was 30 duplicated in oligonucleotide 027 and its complement 032. This sequence, 5'TTACCG-3' was deleted by mutagenesis using the oligonucleotide 5'-GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 70). The resultant vector was designated M13IXF3.

25

30

contains all the functional elements of the previously described M13IXHL vector except that it does not express functional antibody heteromers. The single-stranded vector can be hybridized to populations of single-stranded Hc and Lc encoding sequences for their incorporation into the vector by mutagenesis. Populations of single-stranded Hc and Lc encoding sequences can be produced by one skilled in the art from the PCR products described in Example I or by other methods known to one skilled in the art using the primers and teachings described therein. The resultant vectors with Hc Lc encoding sequences randomly and incorporated are propagated and screened for desired binding specificities as described in Example I.

Other vectors similar to M13IX53 and the vectors it's derived from, M13IX11 and M13IX30, have also been produced for the incorporation of Hc and Lc encoding sequences without restriction. In contrast to M13IX53, these vectors contain human antibody sequences for the efficient hybridization and incorporation of populations of human Hc and Lc sequences. These vectors are briefly described below. The starting vectors were either the Hc vector (M13IX30) or the Lc vector (M13IX11) previously described.

M13IX32 was generated from M13IX30 by removing the six nucleotide redundant sequence 5'-TTACCG-3' described above and mutation of the leader sequence to increase secretion of the product. The oligonucleotide used to remove the redundant sequence is the same as that given above. The mutation in the leader sequence was generated using the oligonucleotide 5'GGGCTTTTGCCACAGGGGT-3'. This mutagenesis resulted in the A residue at position 6353 of M13IX30 being changed to a G residue.

A decapeptide tag for affinity purification of antibody fragments was incorporated in the proper reading frame at the carboxy-terminal end of the Hc expression site

in M13IX32. The oligonucleotide used for this mutagenesis was 5'-CGCCTT CAGCCTAAGAAGCGTAGTCCGGAACGTCGTACGGGTAGGATCCA CTAG-3' (SEQ ID NO: 71). The resultant vector was designated M13IX33. Modifications to this or other vectors are envisioned which include various features known to one skilled in the art. For example, a peptidase cleavage site can be incorporated following the decapeptide tag which allows the antibody to be cleaved from the gene VIII portion of the fusion protein.

M13IX34 (SEQ ID NO: 3) was created from M13IX33 by 10 cloning in the gene encoding a human IgG1 heavy chain. The reading frame of the variable region was changed and a stop codon was introduced to ensure that а polypeptide would not be produced. The oligonucleotide used for the mutagenesis of the variable region was 5'-15 CACCGGTTCGGGGAATTAGTCTTGACCAGGCCAGGGC-3' (SEQ ID NO: The complete nucleotide sequence of this vector is shown in Figure 4 (SEQ ID NO: 3).

Several vectors of the M13IX11 series were also 20 generated to contain similar modifications that described for the vectors M13IX53 and M13IX34. The promoter region in M13IX11 was mutated to conform to the 35 sequence to generate M13IX12. The oligonucleotide used for this mutagenesis was 5'-ATTCCACAC ATTATACGAGCCGGAAGCATAAAGTGTCAAGCCTGGGGTGCC-3' (SEQ ID NO: 25 A human kappa light chain sequence was cloned into M13IX12 and the variable region subsequently deleted to generate M13IX13 (SEQ ID NO: 4). The complete nucleotide sequence of this vector is shown in Figure 5 (SEQ ID NO: 30 A similar vector, designated M13IX14, was also 4). generated in which the human lambda light chain was inserted into M13IX12 followed by deletion of the variable region. The oligonucleotides used for the variable region deletion of . M13IX13 and M13IX14 were 5'-CTG CTCATCAGATGGCGGGAAGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 74) 35

and 5'-GAACAGAGT GACCGAGGGGGGGGGGGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 75), respectively.

The Hc and Lc vectors or modified forms thereof can be combined using the methods described in Example I to produce a single vector similar to M13IX53 that allows the efficient incorporation of human Hc and Lc encoding sequences by mutagenesis. An example of such a vector is the combination of M13IX13 with M13IX34. The complete nucleotide sequence of this vector, M13IX60, is shown in Figure 6 (SEQ ID NO: 5).

Additional modifications to any of the previously described vectors can also be performed to generate vectors which allow the efficient incorporation and surface expression of Hc and Lc sequences. For example, alleviate the use of uracil selection against wild-type template during mutagenesis procedures, the variable region locations within the vectors can be substituted by a set of palindromic restriction enzyme sites (i.e., two similar sites in opposite orientation). The palindromic sites will loop out and hybridize together during the mutagenesis and 20 thus form a double-stranded substrate for restriction endonuclease digestion. Cleavage of the site results in the destruction of the wild-type template. The variable region of the inserted Hc or Lc sequences will not be affected since they will be in single stranded form. 25

Following the methods of Example I, single-stranded Hc or Lc populations can be produced by a variety of methods known to one skilled in the art. For example, the PCR primers described in Example I can be used in asymmetric PCR to generate such populations. 30 Gelfand et al., "PCR Protocols: A Guide to Methods and Applications", Ed by Innis (1990), which is incorporated herein reference. Asymmetric PCR is a PCR method differentially amplifies only a single strand of the double

stranded template. Such differential amplification is accomplished by decreasing the primer amount for the undesirable strand about 10-fold compared to that for the desirable strand. Alternatively, single-stranded 5 populations can be produced from double-stranded PCR products generated as described in Example I except that the primer(s) used to generate the undesirable strand of the double-stranded products is first phosphorylated at its 5' end with a kinase. The resultant products can then be treated with a 5' to 3' exonuclease, such as lambda. exonuclease (BRL, Bethesda, MD) to digest away the unwanted strand.

Single-stranded Hc and Lc populations generated by the methods described above or by others known to one skilled in the art are hybridized to complementary sequences encoded in the previously described vectors. The population of the sequences are subsequently incorporated into a double-stranded form of the vector by polymerase extension of the hybridized templates. Propagation and surface expression of the randomly combined Hc and Lc sequences are performed as described in Example I.

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

#### SEQUENCE LISTING

(1) GENERAL	INFORMATION:
-------------	--------------

- (i) APPLICANT: HUSE, WILLIAM D.
- (ii) TITLE OF INVENTION: SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS
- (iii) NUMBER OF SEQUENCES: 75
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK (B) STREET: 444 SO. FLOWER STREET, SUITE 200

  - (C) CITY: LOS ANGELES (D) STATE: CALIFORNIA
  - (E) COUNTRY: UNITED STATES
  - (F) ZIP: 90071
- (v) COMPUTER READABLE FORM:

  - (A) MEDIUM TYPE: Floppy disk
    (B) COMPUTER: IBM PC compatible
    (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    (D) SOFTWARE: Patentin Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: CAMPBELL, CATHRYN A.
  - (B) REGISTRATION NUMBER: 31,815
  - (C) REFERENCE/DOCKET NUMBER: P31 8882
  - (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: 619-535-9001
    - (B) TELEFAX: 619-535-8949
- (2) INFORMATION FOR SEQ ID NO:1:
  - (1) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 7445 base pairs
    - (B) TYPE: nucleic acid (C) STRANDEDNESS: both

    - (D) TOPOLOGY: circular
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGCAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	. 240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420

CACCCTAA						
CAGGGTAA	AG ACCTGATTI	T TGATTTAT	GG TCATTCTC	CT TTTCTGAA	CT GTTTAAAGCA	480
TTTGAGGG	GG ATTCAATGA	A TATTTATGA	AC GATTCCGC	AG TATTGGAC	GC TATCCAGTCT	540
AAACATTT	TA CTATTACCO	C CTCTGGCA	A ACTICITI	C CAAAAGCC	C TCGCTATTTT	600
GGTTTTTA	C GTCGTCTGG	T AAACGAGG	T TATGATAG	C TIGCICITA	C TATGCCTCGT	660
AATTCCTT	TT GGCGTTATG	T ATCTGCATT	TA GTTGAATGT	G GTATTCCTA	A ATCTCAACTG	720
ATGAATCT	TT CTACCTGTA	A TAATGTTGT	T CCGTTAGTT	C GTTTTATTA	A CGTAGATTTT	780
TCTTCCCAA	C GTCCTGACT	G GTATAATGA	G CCAGTTCTT	A AAATCGCAT	A AGGTAATTCA	840
CAATGATTA	A AGTTGAAAT	T AAACCATCT	C AAGCCCAAT	T TACTACTCG	T TCTGGTGTTT	900
CTCGTCAGG	G CAAGCCTTA	T TCACTGAAT	G AGCAGCTTT	G TTACGTTGA	T TTGGGTAATG	960
AATATCCGG	T TCTTGTCAA	G ATTACTCTT	G ATGAAGGTC	A GCCAGCCTA	T GCGCCTGGTC	1020
TGTACACCG	T TCATCTGTC	C TCTTTCAAA	G TTGGTCAGT	T CGGTTCCCT	T ATGATTGACC	1080
GTCTGCGCC	T CGTTCCGGC	T AAGTAACAT	G GAGCAGGTC	G CGGATTTCG	A CACAATTTAT	1140
CAGGCGATG	A TACAAATCT	CCTTGTACT	T TGTTTCGCG	C TTGGTATAA	I CGCTGGGGGT	1200
CAAAGATGA	G TGTTTTAGT	TATTCTTTC	G CCTCTTTCC	TTTAGGTTG	G TGCCTTCGTA	1260
GTGGCATTA	C GTATTTTACC	CGTTTAATG	G AAACTTCCT	C ATGAAAAAG	CTTTAGTCCT	1320
CAAAGCCTC	T GTAGCCGTTC	CTACCCTCG	T TCCGATGCT	TCTTTCGCT	CTGAGGGTGA	1380
CGATCCCGC	A AAAGCGGCCT	TTAACTCCC	CCAAGCCTC	GCGACCGAA1	ATATCGGTTA	1440
TGCGTGGGC	G ATGGTTGTTG	TCATTGTCG	G CGCAACTAT	GGTATCAAG	TGTTTAAGAA	1500
ATTCACCTC	G AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GCTCCTTT	GGAGCCTTTT	1560
TTTTTGGAG	TTTTCAACGT	GAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TCTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
					TGAGGGTTGT	1740
					TTACGGTACA	1800
					GGGTGGCGGT	1860
					TGATACACCT	1920
					TACTGAGCAA	1980
					TTTCATGTTT	2040
					CACTGTTACT	2100
					AAAAGCCATG	2160
					CTTTAATGAA	
					TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
					TGGTTCCGGT	2400
					AATCCCCAT	2400

CAAAACCCCC	TACACECE					
GAAAACGCGC	TACAGTCTG	A CGCTAAAGG	C AAACTTGAT	T CTGTCGCTA	CTGATTACGGT	2520
GCTGCTATCG	ATGGTTTCA	I TGGTGACGT	T TCCGGCCTT	G CTAATGGTA	A TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTA	A TTCCCAAAT	G GCTCAAGTC	G GTGACGGTG	A TAATTCACCT	2640
TTAATGAATA	ATTTCCGTC	ATATTTACC	T TCCCTCCCT	C AATCGGTTG	A ATGTCGCCCT	2700
TITGTCTTTA	GCGCTGGTA	ACCATATGA	A TITTCTATT	G ATTGTGACA	A AATAAACTTA	2760
					T ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTA	TAAGGAGTC	T TAATCATGC	C AGTTCTTTT	G GGTATTCCGT	2880
TATTATTGCG '	TTTCCTCGGT	TTCCTTCTC	G TAACTTTGT	I CGGCTATCT	CTTACTTTTC	2940
TTAAAAAGGG (	CTTCGGTAAG	ATAGCTATT	CTATTTCAT	CTTTCTTGC	CTTATTATTG	3000
GGCTTAACTC A						3060
TTGTTCAGGG 7						3120
TCTCTGTAAA (						3180
ATTGGGATAA A						3240
CTCGTTAGCG 1						3300
CTTGATTTAA C	GCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC C	GGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG A						3480
ACCCGTTCTT G						3540
AAATTAGGAT G						3600
CGTTCTGCAT T						3660
TTTGTCGGTA C						3720
GTTGGCGTTG T	TAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA A						3840
TCCGGTGTTT A	TTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC A	GAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA T	TGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA A	GGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA AT	ICTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT TA	ACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG GT	TAATTCAAA	TCAAATTCTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA TO						4320
TGTAACTTGG TA						4380
TACTGTTACT GT						4440
TGTTTTACGT GO						45Q0

TARICCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	. , , , , ,
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA	
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	-
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4800
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4860
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT	4920
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	4980
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5040
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5100
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5160
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5220
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	5340
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5400
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG	5460
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5520
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5 <b>58</b> 0
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG	5640
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	570C
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5760
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5820
ACAGGATTIT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5880
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	5940
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6 <b>00</b> 0
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6060
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6120
TTGTGAGCGG ATAACAATTT CACACGCGTC ACTTGGCACT GGCCGTCGTT TTACAACGTC	6180
GTGACTGGGA AAACCCTGGC GTTACCCAAG CTTTGTACAT GGAGAAAATA AAGTGAAACA	6240
AAGCACTATT GCACTGGCAC TCTTACCGTT ACCGTTACTG TTTACCCCTG TGACAAAAGC	630C
CGCCCAGGTC CAGCTGCTCG AGTCACCCCT ATTOTOGGG TTTACCCCTG TGACAAAAGC	636C
CGCCCAGGTC CAGCTGCTCG AGTCAGGCCT ATTGTGCCCA GGGGATTGTA CTAGTGGATC	6420
CTAGGCTGAA GGCGATGACC CTGCTAAGGC TGCATTCAAT AGTTTACAGG CAAGTGCTAC	648C
TGAGTACATT GGCTACGCTT GGGCTATGGT AGTAGTTATA GTTGGTGCTA CCATAGGGAT	6545

TAAATTATT	C 44446					
INVALIATI	C AAAAAGTTTA	CGAGCAAGGC	TTCTTAAGCA	ATAGCGAAGA	GGCCGGCACC	6600
GATCGCCCT	T CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTTGC	CIGGIIICCG	6660
GCACCAGAA	G CGGTGCCGGA	AAGCTGGCTG	GAGTGCGATC	TTCCTGAGGC	CGATACCCTC	
CTCGTCCCC	T CAAACTGGCA	GATGCACGGT	TACGATGCGC	CCATCTACAC	CALCONIA	6720
TATCCCATT	CCCTCLATCO			CCATCIACAC	CAACGTAACC	6780
INICCONTIN	A CGGTCAATCC	GCCGTTTGTT	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	6840
CTCACATTTA	ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTTGAT	6900
GGCGTTCCTA	TTGGTTAAAA	AATGAGCTGA	TTTAACAAAA	ATTTAACGCG	AATTITAACA	6960
AAATATTAAC	GTTTACAATT	TAAATATTTG	CTTATACAAT	CTTCCTGTTT	TTGGGGCTTT	7020
TCTGATTATC	AACCGGGGTA	CATATGATTC	ACATOCTACT	~~~	-100000111	7020
4 TTCTCTTCT			NONTGCTAGT	TITACGATTA	CCGTTCATCG	7080
WITCICITIGI	TTGCTCCAGA	CTCTCAGGCA	ATGACCTGAT	AGCCTTTGTA	GATCTCTCAA	7140
AAATAGCTAC	CCTCTCCGGC	TATTTAATTA	CAGCTAGAAC	GGTTGAATAT	CATATTGATG	7200
GTGATTTGAC	TGTCTCCGGC	CTTTCTCACC	CTTTTGAATC	TTTACCTACA	CATTACTCAC	7260
GCATTGCATT	TAAAATATAT	GAGGGTTCTA	A A A A T-T-T-T-A	### COMMO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	_	7260
CTTCTCCCCC			WWWITITIA	ICCITGCGIT.	GAAATAAAGG	7320
orrerected.	AAAAGTATTA	CAGGGTCATA	ATGTTTTTGG '	TACAACCGAT	TTAGCTTTAT	7380
GCTCTGAGGC	TTTATTGCTT	AATTTTGCTA	ATTCTTTGCC '	TTGCCTGTAT (	CATTTATTCC	7440
ACGTT	•		_			,440
403			•		-	7445

### (2) INFORMATION FOR SEQ ID NO:2:

# (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

			- (			
AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTITA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCCGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTICITITG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTCCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720 >

ATCA ATCTTT CTA COTON	
ATGAATCTIT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TOTTCCCARC GIGGIGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA ACCTIATION	
CARTOATIAN AGIIGAAATT AAACCATCTC AAGCCCAATT TACTACTCCT TCTCCTCT	
CICCICAGG CAAGCCITAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTCCCTLATE	
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT CCCCCTCCTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATCATTGG	1020
GICIGCGCCI CGITCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCCA CACAATTA	
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CCCTGGGGGT	1140
CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTCC TCCCTTTCCT	1200
GIGGCATIAC GIATTITACC CGTTTAATGG AAACTTCCTC ATGAAAAGT CTTTACTCCTC	1260
CAAAC COTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1320
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1380
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1440
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1500
TITTTGGAGA TITTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1560
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1620
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1680
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA	1740
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1800
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1860
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1920
AACCCCGCTA ATCCTAATCC TTCTCTTCAC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT CAGAATAATA GGTTCCGAAA TACCCAGGG CAGATCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCCGCTTCTC ACCOMPANY ACCOM	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
CARACCICCO TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TCATTAGGGT	2520
GCIGCIAICG AIGGITTCAT IGGIGACGIT ICCGGCCITG CIAAIGGIAA ICCICCIACE	258C
OGIGATITIG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCAGGT	2640
TIARIGARIA ATTICCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATCTCCCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2769

TTCCGTCGTC TCTTTCCCTT TCTTTCTT	
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTCGGTA CTTTATATTC TCTTATTACT GGGTCGAAAA TGCCTCTGCC TAAATTACAT	3720
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTTC ACGCGTTCTT	3960
TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG	402C
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC	420C
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT	4320
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	438C
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTTC	444C
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA	468C
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800

AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	
TITITICATIT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4860
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT	4920
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	4980
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5040
TACTGGTCGT GTGACTGGTG AATCTCCCAA TOTALLE	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5220
TACTAATCAA AGAAGTATTG CTACAACCCT TACTAATCAA AGAAGTATTG	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG	5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5580
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG	5700
ATTIGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5820
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5880
ACAGGATTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5940
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6120
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6180
TTGTGAGCGG ATAACAATTT CACACGCCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC	6240
TACGGCAGCC GCTGGATTGT TATTACTCGC TGCCCAACCA GCCATGGCCG AGCTCGTGAT	6300
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAATT CTAGAACGCG TCACTTGGCA	6360
CTTGCACAA TTCCCTTTTC	6420
CCTTGCAGAA TTCCCTTTCG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA CCGATCGCCC	6480
TICCOARCAG TIGUGGAGCC TGAATGGCGA ATGGCGCTTT GCCTGGTTTC GCCGAGGA	6540
AGCOGIGCCO GAAAGCIGGC IGGAGTGCGA ICTICCIGAG GCCGATACCC ICCICCICCI	6600
CICAAACIGG CAGAIGCACG GTTACGATGC GCCCATCTAC ACCAACCTAL CCTATOGO	6660
TACGGICARI CCGCCGIITG TTCCCACGGA GAATCCGACG GGTTGTTACT CCGTGACA	6720
TARTOTICAL GAAAGCTGGC TACAGGAAGG CCAGACGCGA ATTATTTTC ATGGGTTAG	6780
TATTGGTTAA AAAATGAGCT GATTTAACAA AAATTTAACG CGAATTTTAA CAAAATATTA	2215 3

ACGTTTACAA TT	TAAATATT	TGCTTATACA	ATCTTCCTCT	T		
TCAACCGGGG TA		TCACATOR		TITIGGGGCT	TTTCTGATTA	6900
TCAACCGGGG TA	ONTHIUMI	IGACATGCTA	GTTTTACGAT	TACCGTTCAT	CGATTCTCTT	6960
GTTTGCTCCA GA	CTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	A A A A A T A C C C	
ACCCTCTCCG GCA	ATTAATTT	ATCAGCTAGA	ACCCTTCAAT		AAAAATAGCT	7020
ACTOTOTOGO CO	~~~~~		ACGGIIGAAI	ATCATATTGA	TGGTGATTTG	7080
ACTGTCTCCG GCG	SITICICA (	CCCTITTGAA	TCTTTACCTA	CACATTACTC	AGGCATTCCA	7140
TTTAAAATAT ATC	SAGGGTTC 7	TAAAAATTTT	TATCCTTGCG	TTCAAATAAA	2222	/140
GCAAAAGTAT TAC	CAGGGTCA T	FA A TOTAL		TIONANIAAA	GGCTTCTCCC	7200
GCAAAAGTAT TAG	MOUGICA )	CARIGITIT	GGTACAACCG	ATTTAGCTTT	ATGCTCTGAG	7260
GCTTTATTGC TTA	ATTTTGC I	TAATTCTTTG	CCTTGCCTGT .	ATGATTTATT	CC A TOTAL	
(2) INFORMATIO	N FOR SEC	ID NO.3.			CONTGII	7317
	- •					

#### (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7729 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT 60 ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT 120 CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA 180 GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA 240 TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG 300 TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG 360 TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT 420 CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA 480 TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT 540 AAACATTITA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT 600 GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT 660 AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG 720 ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT 780 TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA 840 CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT 900 CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG 960 AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC 1020 TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC 1080 GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT 1140 CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT 1200%

CAAAGATGAG TGTTTTAGTG TATTCTTTCG COTCO	
CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TOCOTOGGE ATGGITGTTG TCATTGTCGG CGCAACTATC GGTATCAACC TCTTTAACA	
ATTCACCICG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT CCACCCTTTT	1560
TITITIGAGA TITITCAACGT GAAAAATTA TTATTCGCAA TTCCTTTAGT TCTTC	
TATICICACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAATTGA	1680
TITACIAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TCACCCTTCT	
CIGIGGAAIG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACCGTAG	1740
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1800
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1860
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1920
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	1980
CAGGATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2040
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2100
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2160
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2220
GCTGGCGGCG GCTCTGGTGG TGGTTCTCCT GGGGCGGCG TGCCTGAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TITGICITIA GUGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TICCGIGGIG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATCT ATTTTCTACC	2820
TITGCTARCA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG CCTATTGGGT	2880
TATTATIGGG TITCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TRAAAAGGG CITCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTC	
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3000
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3060
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3120
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACC	3180
TITLE OF AND TOOCH AND TAGGETS TEGGANAGACT	3245

CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3300
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3360
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	3420
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3480
AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3540
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3600
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	3660
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3720
ACTGGTAAGA ATTTGTATAA CGCATATCAT ACTALLONDO	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTTC ACGCGTTCTT	3960
TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC	4200
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT	4320
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	4380
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTTC	4440
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5280

TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5345
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	5340
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5400
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGCGGCGG	5460
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5520
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5580
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG	5640
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5700
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5760
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5820
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5880
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	5940
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGGCTCCCT	6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6120
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6180
TTGTGAGCGG ATAACAATTT CACACGCGTC ACTTGGCACT GGCCGTCGTT TTACAACGTC	6240
GTGACTGGGA AAACCCTGGC GTTACCCAAG CTTTGTACAT GGAGAAAATA AAGTGAAACA	6300
AAGCACTATT GCACTGGCAC TCTTACCGTT ACTGTTTACC CCTGTGGCAA AAGCCCAGGT	6360
CCAGCTGCTC GAGTCGGTCT TCCCCCTGGC ACCCTCCTCC AAGAGCACCT CTGGGGGCAC	6420
AGCGGCCCTG GGCTGCCTGG TCAAGACTAA TTCCCCGAAC CGGTGACGGT GTCGTGGAAC	6480
TCAGGCGCCC TGACCAGCGG CGTGCACACC TTCCCGGCTG TCCTACAGTC CTCAGGACTC	6540
TACTCCCTCA GCAGCGTGGT GACCGTGCCC TCCAGCAGCT TGGGCACCCA GACCTACATC	6600
TGCAACGTGA ATCACAAGCC CAGCAACACC AAGGTGGACA AGAAAGCAGA GCCCAAATCT	6660
TGTACTAGTG GATCCTACCC GTACGACGTT CCGGACTACG CTTCTTAGGC TGAAGGCGAT	6720
GACCCTGCTA AGGCTGCATT CAATAGTTTA CAGGCAAGTG CTACTGAGTA CATTGGCTAC	6780
GCTTGGGCTA TGGTAGTAGT TATAGTTGGT GCTACCATAG GGATTAAATT ATTCAAAAAG	6840
TTTACGAGCA AGGCTTCTTA AGCAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC	6900
AGTTGCGCAG CCTGAATGGC GAATGGCGCT TTGCCTGGTT TCCGGCACCA GAAGCGGTGC	6960
CGGAAAGCTG GCTGGAGTGC GATCTTCCTG AGGCCGATAC GGTCGTCGTC CCCTCAAACT	7020
GGCAGATGCA CGGTTACGAT GCGCCCATCT ACACCAACGT AACCTATCCC ATTACGGTCA	7080
ATCCGCCGTT TGTTCCCACG GAGAATCCGA CGGGTTGTTA CTCGCTCACA TTTAATGTTG	7140
ATGAAAGCTG GCTACAGGAA GGCCAGACGC GAATTATTTT TGATGGCGTT CCTATTGGTT	720C
AAAAAATGAG CTGATTTAAC AAAAATTTAA CGCGAATTTT AACAAAATAT TAACGTTTAC	7260
AATTTAAATA TTTGCTTATA CAATCTTCCT GTTTTTGGGG CTTTTCTGAT TATCAACCGG	7338
	. > ===

GGTACATATG ATTGACATGC TAGTTTTACG ATTACCGTTC ATCGATTCTC TTG	-
CAGACTETCA GGCAATGACC TGATAGCCTT TGTAGATCTC TCAAAAATAG CTA	7380
CGGCATTAAT TTATCAGCTA GAACGGTTGA ATATCATATT GATGGTGATT TGA	ACCCTCTC 7440
CGGCCTTTCT CACCCTTTTG AATCTTTACC TACACATTAC TCAGGCATTG CAT	CTGTCTC 7500
ATATGAGGGT TCTAAAAATT TTTATCCTTG CGTTGAAATA AAGGCTTCTC CCG	TTAAAAT 7560
ATTACAGGGT CATAATGTTT TTGGTAGAAG GGTTGTA AAGGGTTCTC CCG	CAAAAGT 7620
ATTACAGGGT CATAATGTTT TTGGTACAAC CGATTTAGCT TTATGCTCTG AGGG	CTTTATT 7680
GCTTAATTTT GCTAATTCTT TGCCTTGCCT GTATGATTTA TTGGACGTT  (2) INFORMATION FOR SEQ ID NO:4:	7729
TOR SEQ ID NO:4:	

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7557 base pairs
  (B) TYPE: nucleic acid
  (C) STRANDEDNESS: both
  (D) TOPOLOGY: circular

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:4:

SEQ ID NO:4:	
AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAATG	
ATAGCTAAAC AGGTTATTGA CCATTTCCCA AATOTTATT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	120
CTTCCATACA CCGTACTTTA	180
STISSARIATI TARARCATGT TGAGCTACAG CACCAGATTC AGCAATTAAC CTCT	240
TOOGRAAM TGACCICTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTCAAATCA	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG	300
TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT	360
CAGGGTAAAC ACCTGATTATA TA	420
CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	
AAACATTTTA CTATTACCCC CTCTCCCAAA ACTTCCTTTA	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	600
AATTCCTTAC TATGCCTCGT	660
CALIFOCITIT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTGAAGATGTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	. 20
TCTTCCCAAC CTCCTCACTC CT. T. T	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT	000
CTCGTCAGGG CAAGCCTTAT TCACTGAATG ACCACGTTTTE	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	
TGTACACCGT TCATCTCTCC TCTTTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT	1000
CAGGCGATGA TACAAATGTG COORD	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CHARACTER TATTCTTTCG CCTCTTTCCT TTTLCCTTTC	
TAMOULIGO LOCULTEGTA	1261 -

GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT	
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1320
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	_
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA	-
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1500
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1560
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1620
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1680
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA	1740
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1800
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1860
ATTCCGGGCT ATACTTATAT CAACCTCTC CAGGGCTACGC TGATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT CAGAATAATA GGTTCCGAAA TACCCACGG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGGATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CCTGTTTCTT GCTCTTATTA TTGGGCTTAA	3000
CICAATTCTT GTGGGTTATC TCTCTGATAT TAGCGCTCAA TTACCCTCTG ACTTTGTTCA	3060
GGGIGTTCAG TTAATTCTCC CGTCTAATGC GCTTCCCTGT TTTTATGTTA TTCTCTCTCT	3120
AAAGGCTGCT ATTTTCATTT TTGACGTTAA ACAAAAATC GTTTCTTATT TGGATTGGG	3180
TAAATAATAT GGCTGTTTAT TTTGTAACTG GCAAATTAGG CTCTGGAAAG ACGCTCGTTA	3240
GCGTTGGTAA GATTCAGGAT AAAATTGTAG STGGGTGCAA AATAGCAAST AATCTTGATT	3305

TARGUETTCA AAACCTCCCG CAAGTCGGGA GGTTCGCTAA AACGCCTCGC GTTCTTAGAA	3360
TACCGGATAA GCCTTCTATA TCTGATTTGC TTGCTATTGG GCGCGGTAAT GATTCCTACC	2/00
ATGAAAATAA AAACGGCTTG CTTGTTCTCG ATGAGTGCGG TACTTGGTTT AATACCCGTT	
CTTGGAATGA TAAGGAAAGA CAGCCGATTA TTGATTGGTT TCTACATGCT CGTAAATTAG	
GATGGGATAT TATTTTTCTT GTTCAGGACT TATCTATTGT TGATAAACAG GCGCGTTCTG	3540
CATTAGCTGA ACATGTTGTT TATTGTCGTC GTCTGGACAG AATTACTTTA CCTTTTGTCG	3600
GTACTITATA TICTCTTATI ACTGGCTCGA AAATGCCTCT GCCTAAATTA CATGTTGGCG	3660
TTGTTAAATA TGGCGATTCT CAATTAAGCC CTACTGTTGA GCGTTGGCTT TATACTGGTA	3720
AGAATTTGTA TAACGCATAT GATACTAAAC AGGCTTTTTC TAGTAATTAT GATTCCGGTG	3780
TTTATTCTTA TTTAACGCCT TATTTATCAC ACGGTCGGTA TTTCAAACCA TTAAATTTAG	3840
GTCAGAAGAT GAAGCTTACT AAAATATATT TGAAAAAGTT TTCACGCGTT CTTTGTCTTG	3900
CGATTGGATT TGCATCAGCA TITACATATA GTTATATAAC CCAACCTAAG CCGGAGGTTA	3960
AAAAGGTAGT CTCTCAGACC TATGATTTTG ATAAATTCAC TATTGACTCT TCTCAGCGTC	4020
TTAATCTAAG CTATCGCTAT GTTTTCAAGG ATTCTAAGGG AAAATTAATT AATAGCGACG	4080
ATTTACAGAA GCAAGGTTAT TCACTCACAT ATTTACAGA AAAATTAATT AATAGCGACG	4140
ATTTACAGAA GCAAGGTTAT TCACTCACAT ATATTGATTT ATGTACTGTT TCCATTAAAA	4200
AAGGTAATTC AAATGAAATT GTTAAATGTA ATTAATTTTG TTTTCTTGAT GTTTGTTTCA	4260
TCATCTTCTT TTGCTCAGGT AATTGAAATG AATAATTCGC CTCTGCGCGA TTTTGTAACT	4320
TGGTATTCAA AGCAATCAGG CGAATCCGTT ATTGTTTCTC CCGATGTAAA AGGTACTGTT	4380
ACTGTATATT CATCTGACGT TAAACCTGAA AATCTACGCA ATTTCTTTAT TTCTGTTTTA	4440
CGTGCTAATA ATTTTGATAT GGTTGGTTCA ATTCCTTCCA TAATTCAGAA GTATAATCCA	4500
AACAATCAGG ATTATATTGA TGAATTGCCA TCATCTGATA ATCAGGAATA TGATGATAAT	4560
TCCGCTCCTT CTGGTGGTTT CTTTGTTCCG CAAAATGATA ATGTTACTCA AACTTTTAAA	4620
ATTAATAACG TTCGGGCAAA GGATTTAATA CGAGTTGTCG AATTGTTTGT AAAGTCTAAT	4680
ACTTCTAAAT CCTCAAATGT ATTATCTATT GACGGCTCTA ATCTATTAGT TGTTAGTGCA	4740
CCTAAAGATA TTTTAGATAA CCTTCCTCAA TTCCTTTCTA CTGTTGATTT GCCAACTGAC	4800
CAGATATTGA TTGAGGGTTT GATATTTGAG GTTCAGCAAG GTGATGCTTT AGATTTTTCA	4860
TTTGCTGCTG GCTCTCAGCG TGGCACTGTT GCAGGCGGTG TTAATACTGA CCGCCTCACC	4920
TCTGTTTTAT CTTCTGCTGG TGGTTCGTTC GGTATTTTTA ATGGCGATGT TTTAGGGCTA	4980
TCAGTTCGCG CATTAAAGAC TAATAGCCAT TCAAAAATAT TGTCTGTGCC ACGTATTCTT	5040
ACGCTTTCAG GTCAGAAGGG TTCTATCTCT GTTGGCCAGA ATGTCCCTTT TATTACTGGT	5100
CGTGTGACTG GTGAATCTGC CAATGTAAAT AATCCATTTC AGACGATTGA GCGTCAAAAT	5160
GTAGGTATTT CCATGAGCGT TTTTCCTGTT GCAATGGCTG GCGGTAATAT TGTTCTGGAT	
ATTACCAGCA AGGCCGATAG TTTGAGTTCT TCTACTCAGG CAAGTGATGT TATTACTAAT	5220
CAAAGAAGTA TTGCTACAAC GGTTAATTTG CGTGATGGAC AGACTCTTTT ACTCGGTGGC	5280
	53404

CTCACTGATT ATAAAAACAC TTCTCAAGAT TCTGGCGTAC CGTTCCTGTC TAAAATCCCT	5/00
TTAATCGGCC TCCTGTTTAG CTCCCGCTCT GATTCCAACG AGGAAAGCAC GTTATACGTG	5400
CTCGTCAAAG CAACCATAGT ACGCGCCCTG TAGCGGCGCA TTAAGCGCGG CGGGTGTGGT	5460
GGTTACGCGC AGCGTGACCG CTACACTTGC CAGCGCCCTA GCGCCCGCTC CTTTCGCTTT	5520
CTTCCCTTCC TTTCTCGCCA CGTTCGCCGG CTTTCCCCGT CAAGCTCTAA ATCGGGGGCT	5580
CCCTTTAGGG TTCCGATTTA GTGCTTTACG GCACCTCGAC CCCAAAAAAC TTGATTTGGG	5640
TGATGGTTCA CGTAGTGGGC CATCGCCCTG ATAGACGGTT TTTCGCCCTT TGACGTTGGA	5700
GTCCACGTTC TTTAATAGTG GACTCTTGTT CCAAACTGGA ACAACACTCA ACCCTATCTC	5760
GGGCTATTCT TTTGATTTAT AAGGGATTTT GCCGATTTCG GAACCACCAT CAAACAGGAT	5820
TTTCGCCTGC TGGGGCAAAC CAGCGTGGAC CGCTTGCTGC AACTCTCTCA GGGCCAGGCG	5880
GTGAAGGGCA ATCAGCTGTT GCCCGTCTCG CTGGTGAAAA GAAAAACCAC CCTGGCGCCC	5940
AATACGCAAA CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG	6000
GTTTCCCGAC TGGAAAGCGG GCAGTGAGCG CAACGCAATT AATGTGAGTT AGCTCACTCA	6060
TTAGGCACCC CAGGCTTTAC ACTITATGCT TCCGGCTCGT ATGTTGTGTG GAATTGTGAG	6120
CGGATAACAA TITCACACGC CAAGGAGACA GTCATAATGA AATACCTATT GCCTACGGCA	6180
GCCGCTGGAT TGTTATTACT CGCTGCCCAA CCAGCCATGG CCGAGCTCTT CCCGCCATCT	6240
GATGAGCAGT TGAAATCTGG AACTGCCTCT GTTGTGTGCC TGCTGAATAA CTTCTATCCC	6300
AGAGAGGCCA AAGTACAGTG GAAGGTGGAT AACGCCCTCC AATCGGGTAA CTCCCAGGAG	6360
AGTGTCACAG AGCAGGACAG CAAGGACAGC ACCTACAGCC TCAGCAGCAC CCTGACGCTG	6420
AGCAAAGCAG ACTACGAGAA ACACAAAGTC TACGCCTGCG AAGTCACCCA TCAGGGCCTG	6480
AGCTCGCCCG TCACAAAGAG CTTCAACAGG GGAGAGTGTT CTAGAACGCG TCACTTGGCA	6540
CTGGCCGTCG TTTTACAACG TCGTGACTGG GAAAACCCTG GCGTTACCCA AGCTTAATCG	6600
CCTTGCAGAA TTCCCTTTCG CCAGCTGGCG TAATAGCGAA GAGGCCCGCA CCGATCGCCC	6660
TTCCCAACAG TTGCGCAGCC TGAATGGCGA ATGGCGCTTT GCCTGGTTTC CGGCACCAGA	6720
AGCGGTGCCG GAAAGCTGGC TGGAGTGCGA TCTTCCTGAG GCCGATACGG TCGTCGTCCC	6780
CTCAAACTGG CAGATGCACG GTTACGATGC GCCCATCTAC ACCAACGTAA CCTATCCCAT	6840
TACGGTCAAT CCGCCGTTTG TTCCCACGGA GAATCCGACG GGTTGTTACT CGCTCACATT	6900
TAATGTTGAT GAAAGCTGGC TACAGGAAGG CCAGACGCGA ATTATTTTTG ATGGCGTTCC	6960
TATTGGTTAA AAAATGAGCT GATTTAACAA AAATTTAACG CGAATTTTAA CAAAATATTA	7020
ACGTTTACAA TITAAATATT TGCTTATACA ATCTTCCTGT TTTTGGGGCT TTTCTGATTA	7080
TCAACCGGGG TACATATGAT TGACATGCTA GTTTTACGAT TACCGTTCAT CGATTCTCTT	7140
GTTTGCTCCA GACTCTCAGG CAATGACCTG ATAGCCTTTG TAGATCTCTC AAAAATAGCT	7200
ACCCTCTCCG GCATTAATTT ATCAGCTAGA ACGGTTGAAT ATCATATTGA TGGTGATTTG	7260
ACTGTCTCCG GCCTTTCTCA CCCTTTTGAA TCTTTACCTA CACATTACTC AGGCATTGCA	7320
CACATTACTO AGGCATTGCA	7351

TITAAAATAT ATGAGGGTTC TAAAAATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC 7440
GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG 7500
GCTTTATTGC TTAATTTTGC TAATTCTTTG CCTTGCCTGT ATGATTTATT GGATGTT 7557
(2) INFORMATION FOR SEO ID NO:5:

#### (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8118 base pairs (B) TYPE: nucleic acid
- (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT 60 ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA 120 180 GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA 240 TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG 300 TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG 360 TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT 420 CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA 480 TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT 540 AAACATTITA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT 600 GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT 660 AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG 720 ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT 780 TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA 840 CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT 900 CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG 960 AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC 1020 TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC 1080 GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTGGA CACAATTTAT 1140 CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT 1200 CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA 1260 GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT 1320 CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA 1380 CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA 1440 TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA 1500 (

TITTECAGA TITTECAGA TAGAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTT	
TTTTTGGAGA TTTTCAACGT GAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1560
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1620
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1680
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA	1740
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1800
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1860
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1920
AACCCCGCTA ATCCTAATCC TTCTCTTCAC CACTGCTATA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGGATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT GCTGGCGGGG GCTCTGGTGC TCCTTGTGAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT GATTTTGATT ATGAAAACAT CCCAAAGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTI CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TIGTICAGGG IGTICAGTTA ATTICTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TOTOTGTANA GGCIGCTATT TTCATTTTTG ACGTTAAACA AAAAATCCTT TCTTATTTTT	3180
MIGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAALALA	3240
GIGGIAGGG IIGGIAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT ACGAAGTAA	3300
OTIGATITAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCT444AC CCCTGGGGAG	3360
CITAGRATAC COGRIFAGCC TTCTATATCT GATTTGCTTG CTATTCCCCC CCCT. TO. T	3420
TOC. ACCREC AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCCCTAC TTCCTTTAL	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCCT	35400

AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3400
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	
TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA	3840
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTTC ACGCGTTCTT	3900
TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG	3960
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT	4020
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4080
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATC TACTGTTTCC	4140
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4200
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT	4260
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	4320
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTTC	4380
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA	4440
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4500
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4560
TTTTAAAATT AATAACGTTC GGCCAAAGG TTTTAAAATT AATAACGTTC GGCCAAAGG	4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA GTCTAATACT TCTAAATCCT CAAATCTATT ATGTTTAT	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT TAGTGCACCT AAAGATATTT TAGATAACCT TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	540C
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGCGGGGGGG	5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	558%

TEGETITETT CECTTECTIT CTEGECACGT TEGECGGETT TECCEGTEAA GETETAAATE	5 ( , o
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG	5640
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5700
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5760
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5820
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	5880
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	5940
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6000
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6060
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6120 6180
TTGTGAGCGG ATAACAATTT CACACGCCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC	6240
TACGGCAGCC GCTGGATTGT TATTACTCGC TGCCCAACCA GCCATGGCCG AGCTCTTCCC	6300
GCCATCTGAT GAGCAGTTGA AATCTGGAAC TGCCTCTGTT GTGTGCCTGC TGAATAACTT	6360
CTATCCCAGA GAGGCCAAAG TACAGTGGAA GGTGGATAAC GCCCTCCAAT CGGGTAACTC	6420
CCAGGAGAGT GTCACAGAGC AGGACAGCAA GGACAGCACC TACAGCCTCA GCAGCACCCT	6480
GACGCTGAGC AAAGCAGACT ACGAGAAACA CAAAGTCTAC GCCTGCGAAG TCACCCATCA	6540
GGGCCTGAGC TCGCCCGTCA CAAAGAGCTT CAACAGGGGA GAGTGTTCTA GAACGCGTCA	6600
CTTGGCACTG GCCGTCGTTT TACAACGTCG TGACTGGGAA AACCCTGGCG TTACCCAAGC	6660
TTTGTACATG GAGAAAATAA AGTGAAACAA AGCACTATTG CACTGGCACT CTTACCGTTA	6720
CTGTTTACCC CTGTGGCAAA AGCCGCCTCC ACCAAGGGCC CATCGGTCTT CCCCCTGGCA	6780
CCCTCCTCCA AGAGCACCTC TGGGGGCACA GCGGCCCTGG GCTGCCTGGT CAAGACTAAT	6840
TCCCCGAACC GGTGACGGTG TCGTGGAACT CAGGCGCCCT GACCAGCGGC GTGCACACCT	6900
TCCCGGCTGT CCTACAGTCC TCAGGACTCT ACTCCCTCAG CAGCGTGGTG ACCGTGCCCT	6960
CCAGCAGCTT GGGCACCCAG ACCTACATCT GCAACGTGAA TCACAAGCCC AGCAACACCA	7020
AGGTGGACAA GAAAGCAGAG CCCAAATCTT GTACTAGTGG ATCCTACCCG TACGACGTTC	7080
CGGACTACGC TTCTTAGGCT GAAGGCGATG ACCCTGCTAA GGCTGCATTC AATAGTTTAC	7140
AGGCAAGTGC TACTGAGTAC ATTGGCTACG CTTGGGCTAT GGTAGTAGTT ATAGTTGGTG	7200
CTACCATAGG GATTAAATTA TTCAAAAAGT TTACGAGCAA GGCTTCTTAA GCAATAGCGA	7260
AGAGGCCCGC ACCGATCGCC CTTCCCAACA GTTGCGCAGC CTGAATGGCG AATGGCGCTT	7320
TGCCTGGTTT CCGGCACCAG AAGCGGTGCC GGAAAGCTGG CTGGAGTGCG ATCTTCCTGA	7380
GGCCGATACG GTCGTCGTCC CCTCAAACTG GCAGATGCAC GGTTACGATG CGCCCATCTA	7440
CACCAACGTA ACCTATCCCA TTACGGTCAA TCCGCCGTTT GTTCCCACGG AGAATCCGAC	7500
GGGTTGTTAC TCGCTCACAT TTAATGTTGA TGAAAGCTGG CTACAGGAAG GCCAGACGCG	7560
AATTATTTTT GATGGGGTTG CTATTGGTTA AAAAATGAGC TGATTTAACA AAAATTTAAC	762C

000.	
GCGAATTTTA ACAAAATATT AACGTTTACA ATTTAAATAT TTGCTTATAC AATCTTCCTG	7680
TTTTTGGGGC TTTTCTGATT ATCAACCGGG GTACATATGA TTGACATGCT AGTTTTACGA	
TTACCGTTCA TCGATTCTCT TGTTTGCTCC AGACTCTCAG GCAATGACCT GATAGCCTTT	. 7740
GTAGATCTCT CAAAAATAGC TACCCTCTCC GGCATTAATT TATCAGCTAG AACGGTTGAA	7800
TATCATATTG ATGGTGATTT GACTGTCTCC GGCCTTTCTC ACCCTTTTGA ATCTTTACCT	7860
ACACATTACT CACCCATTCS ATTITUDE TO	7920
ACACATTACT CAGGCATTGC ATTTAAAATA TATGAGGGTT CTAAAAATTT TTATCCTTGC	7980
GTTGAAATAA AGGCTTCTCC CGCAAAAGTA TTACAGGGTC ATAATGTTTT TGGTACAACC	8040
GATTTAGCTT TATGCTCTGA GGCTTTATTG CTTAATTTTG CTAATTCTTT GCCTTGCCTG	8100
TATGATTTAT TGGACGTT	
(2) INFORMATION FOR SEC ID NO. 6.	8118

#### (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

#### (ix) FEATURE:

- (A) NAME/KEY: misc difference (B) LOCATION: replace(5, "")
- (D) OTHER INFORMATION: /note- "S REPRESENTS EQUAL MIXTURE OF G AND C"

#### (ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(6, "")
- (D) OTHER INFORMATION: /note- "M REPRESENTS EQUAL MIXTURE

#### (ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(8, "")
- (D) OTHER INFORMATION: /note- "R REPRESENTS EQUAL MIXTURE

#### (ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(11, "")
- (D) OTHER INFORMATION: /note- "K REPRESENTS EQUAL MIXTURE

#### (ix) FEATURE:

- (A) NAME/KEY: misc\_difference
- (B) LOCATION: replace(20, "")
- (D) OTHER INFORMATION: /note- "W REPRESENTS EQUAL MIXTURE OF A AND T"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

(2) INFORMATION FOR SEQ ID NO:7:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:	
AGGTCCAGCT GCTCGAGTCT GG	
(2) INFORMATION FOR SEQ ID NO:8:	22
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 22 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
AGGTCCAGCT GCTCGAGTCA GG	
(2) INFORMATION FOR SEQ ID NO:9:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	
AGGTCCAGCT TCTCGAGTCT GG	
(2) INFORMATION FOR SEQ ID NO:10:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	
AGGTCCAGCT TCTCGAGTCA GG	
(2) INFORMATION FOR SEQ ID NO:11:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
AGGTCCAACT GCTCGAGTCT GG	
(2) INFORMATION FOR SEQ ID NO:12:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
AGGTCCAACT GCTCGAGTCA GG	
(2) INFORMATION FOR SEQ ID NO:13:	. 22
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 22 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
AGGTCCAACT TCTCGAGTCT GG	
(2) INFORMATION FOR SEQ ID NO:14:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(x1) SFOURNCE DESCRIPTION	•
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:14: AGGTCCAACT TCTCGAGTCA GG	
(2) INFORMATION FOR SEQ ID NO:15:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
<pre>(ix) FEATURE:     (A) NAME/KEY: misc_difference     (B) LOCATION: replace(56, "")     (D) OTHER INFORMATION: /note= "N=INOSINE"</pre>	
(ix) FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(8, "")  (D) OTHER INFORMATION:	

<pre>(ix) FEATURE:     (A) NAME/KEY: misc_dift.rence     (B) LOCATION: replace(11, "")     (D) OTHER INFORMATION: /note= "N-INOSINE"</pre>	
(ix) FEATURE:  (A) NAME/KEY: misc_difference  (B) LOCATION: replace(20, "")  (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE  OF A AND T"	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
AGGTNNANCT NCTCGAGTCW GG	22
(2) INFORMATION FOR SEQ ID NO:16:	22
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 38 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:	
CTATTAACTA GTAACGGTAA CAGTGGTGCC TTGCCCCA	38
(2) INFORMATION FOR SEQ ID NO:17:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 30 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:	
AGGCTTACTA GTACAATCCC TGGGCACAAT	30
(2) INFORMATION FOR SEQ ID NO:18:	30
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:	
CCAGTTCCGA GCTCGTTGTG ACTCAGGAAT CT	32
(2) INFORMATION FOR SEQ ID NO:19:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 32 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
CCAGTTCCGA GCTCGTGTTG ACGCAGCCGC CC	
(2) INFORMATION FOR SEQ ID NO:20:	32
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
CCAGTTCCGA GCTCGTGCTC ACCCAGTCTC CA	
(2) INFORMATION FOR SEQ ID NO:21:	32
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
CCAGTTCCGA GCTCCAGATG ACCCAGTCTC CA	
(2) INFORMATION FOR SEQ ID NO:22:	32
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 32 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	
CCAGATGTGA GCTCGTGATG ACCCAGACTC CA	
(2) INFORMATION FOR SEQ ID NO:23:	32
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
CCAGATGTGA GCTCGTCATG ACCCAGTCTC CA	
(2) INFORMATION FOR SEQ ID NO:24:	32
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
CCAGTTCCGA GCTCGTGATG ACACAGTCTC CA	
(2) INFORMATION FOR SEQ ID NO:25:	3
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(x1) EQUENCE DESCRIPTION: SEQ ID NO:25:	
GCAGCATTCT AGAGTTTCAG CTCCAGCTTG CC	32
(2) INFORMATION FOR SEQ ID NO:26:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 34 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:	-
GCGCCGTCTA GAATTAACAC TCATTCCTGT TGAA	-
(2) INFORMATION FOR SEQ ID NO:27:	34
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 37 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC	
(2) INFORMATION FOR SEQ ID NO:28:	37
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 35 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
ATTCAATAGT TTACAGGCAA GTGCTACTGA GTACA	
STOCIACION GIACA	35

(2) INFORMATION FOR SEQ ID NO:29:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 35 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
TTGGCTACGC TTGGGCTATG GTAGTTATAGTT	
(2) INFORMATION FOR SEQ ID NO:30:	35
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 35 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
	•
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	
GGTGCTACCA TAGGGATTAA ATTATTCAAA AAGTT	2.5
(2) INFORMATION FOR SEQ ID NO:31:	35
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 18 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	
TACGAGCAAG GCTTCTTA	
(2) INFORMATION FOR SEQ ID NO:32:	18
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:	
AGCTTAAGAA GCCTTGCTCG TAAACTTTTT GAATAATTT	39
(2) INFORMATION FOR SEQ ID NO:33:	,
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 36 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> </ul>	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:	
AATCCCTATG GTAGCACCAA CTATAACTAC TACCAT	3
(2) INFORMATION FOR SEQ ID NO:34:	,
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 35 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:	
AGCCCAAGCG TAGCCAATGT ACTCAGTAGC ACTTG	35
(2) INFORMATION FOR SEQ ID NO:35:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 34 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:	
CCTGTAAACT ATTGAATGCA GCCTTAGCAG GGTC	34
(2) INFORMATION FOR SEQ ID NO:36:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 16 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:	
ATCGCCTTCA GCCTAG	16
(2) INFORMATION FOR SEQ ID NO:37:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 21 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:	
CATTTTTGCA GATGGCTTAG A	. 21
(2) INFORMATION FOR SEQ ID NO:38:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 18 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	7

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:	
TAGCATTAAC GTCCAATA	
(2) INFORMATION FOR SEQ ID NO:39:	18
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 26 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:39:	
ATATATTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:40:	26
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 23 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:	
GACAAAGAAC GCGTGAAAAC TTT	23
(2) INFORMATION FOR SEQ ID NO:41:	23
(1) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 35 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:	
GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT	35
(2) INFORMATION FOR SEQ ID NO:42:	33
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 43 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:	
AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTTA TCC	43

(2) INFORMATION FOR SEQ ID NO:43:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 43 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:	
GGCGAAAGGG AATTCTGCAA GGCGATTAAG CTTGGGTAAC GCC	4;
(2) INFORMATION FOR SEQ ID NO:44:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	·
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:	
GGCGTTACCC AAGCTTTGTA CATGGAGAAA ATAAAG	36
(2) INFORMATION FOR SEQ ID NO:45:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	·
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:	
TGAAACAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT	42
(2) INFORMATION FOR SEQ ID NO:46:	7.
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:	
TACTGTTTAC CCCTGTGACA AAAGCCGCCC AGGTCCAGCT GC	
(2) INFORMATION FOR SEQ ID NO:47:	42
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 44 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:	
TCGAGTCAGG CCTATTGTGC CCAGGGATTG TACTAGTGGA TCCG	
(2) INFORMATION FOR SEQ ID NO:48:	44
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 38 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:	
TGGCGAAAGG GAATTCGGAT CCACTAGTAC AATCCCTG	
(2) INFORMATION FOR SEQ ID NO:49:	. 38
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:	
GGCACAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT	- 42
(2) INFORMATION FOR SEQ ID NO:50:	~~
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
TTGTCACAGG GGTAAACAGT AACGGTAACG GTAAGTGTGC CA	42
(2) INFORMATION FOR SEQ ID NO:51:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:	
GTGCAATAGT GCTTTGTTTC ACTTTATTTT CTCCATGTAC AA	42
(2) INFORMATION FOR SEQ ID NO:52:	. 42
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 21 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:52:	
TAACGGTAAG AGTGCCAGTG C	
(2) INFORMATION FOR SEQ ID NO:53:	21
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:	
CACCTTCATG AATTCGGCAA GGAGACAGTC AT	
(2) INFORMATION FOR SEQ ID NO:54:	32
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 22 base pairs  (P) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	·
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:	
AATTCGCCAA GGAGACAGTC AT	•
(2) INFORMATION FOR SEQ ID NO:55:	22
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANT DNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:	
AATGAAATAC CTATTGCCTA CGGCAGCCGC TGGATTGTT	
(2) INFORMATION FOR SEQ ID NO:56:	39
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:	
ATTACTCGCT GCCCAACCAG CCATGGCCGA GCTCGTGAT	39

(2) INFORMATION FOR SEQ ID NO:57:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:	
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAAT	
(2) INFORMATION FOR SEQ ID NO:58:	39
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 13 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: TCTAGAACGC GTC	
	13
(2) INFORMATION FOR SEQ ID NO:59:	
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 45 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	-
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:	
TTCAGGTTGA AGCTTACGCG TTCTAGAATT AACACTCATT CCTGT	
(2) INFORMATION FOR SEQ ID NO:60:	45
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:	
TGGATATCTG GAGTCTGGGT CATCACGAGC TCGGCCATG	
(2) INFORMATION FOR SEQ ID NO:61:	39
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 39 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single	

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:61:	
GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC	
(2) INFORMATION FOR SEQ ID NO:62:	39
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 37 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:	
GTAGGCAATA GGTATTTCAT TATGACTGTC CTTGGCG	
(2) INFORMATION FOR SEQ ID NO:63:	37
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 30 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:	
TGACTGTCTC CTTGGCGTGT GAAATTGTTA	
(2) INFORMATION FOR SEQ ID NO:64:	30
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 36 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:	
TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT	
(2) INFORMATION FOR SEQ ID NO:65:	36
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	·
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:	
GCCAGTGCCA AGTGACGCGT TCTA	<b>A</b> :
(2) INFORMATION FOR SEQ ID NO:66:	. 24
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 26 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:	
ATATATTTA GTAAGCTTCA TCTTCT	2
(2) INFORMATION FOR SEQ ID NO:67:	26
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 23 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:	
GACAAAGAAC GCGTGAAAAC TTT	
(2) INFORMATION FOR SEQ ID NO:68:	23
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 76 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:	
	-
CTGAACCTGT CTGGGACCAC AGTTGATGCT ATAGGATCAG ATCTAGAATT CATTTAGAGA CTGGCCTGGC TTCTGC	60
(2) INFORMATION FOR SEQ ID NO:69:	76
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 80 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:	
TCGACCGTTG GTAGGAATAA TGCAATTAAT GGAGTAGCTC TAAATTCAGA ATTCATCTAC	
ACCCAGTGCA TCCAGTAGCT	60
(2) INFORMATION FOR SEQ ID NO:70:	80
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 27 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:	

GGTAAACAGT AACGGTAAGA GTGCCAG

(2) INFORMATION FOR SEQ ID NO:71:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 54 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:	
CGCCTTCAGC CTAAGAAGCG TAGTCCGGAA CGTCGTACGG GTAGGATCCA CTAG	54
(2) INFORMATION FOR SEQ ID NO:72:	-
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 41 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:	
CACCGGTTCG GGGAATTAGT CTTGACCAGG CAGCCCAGGG C	41
(2) INFORMATION FOR SEQ ID NO:73:	~ •
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 51 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:	
ATTCCACACA TTATACGAGC CGGAAGCATA AAGTGTCAAG CCTGGGGTGC C	51
(2) INFORMATION FOR SEQ ID NO:74:	3.
(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 42 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:	
CTGCTCATCA GATGGCGGGA AGAGCTCGGC CATGGCTGGT TG	42
(2) INFORMATION FOR SEQ ID NO:75:	-
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 42 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:
GAACAGAGTG ACCGAGGGGG CGAGCTCGGC CATGGCTGGT TG

I Claim:

- 1. A composition of matter comprising a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form heteromeric receptors, one or both of said polypeptides being expressed as fusion proteins on the surface of a cell.
- 2. The composition of claim 1, wherein said plurality of cells are  $\underline{E.\ coli}$ .
- 3. The composition of claim 1, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 4. The composition of claim 1, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 5. The composition of claim 4, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 6. The composition of claim 1, wherein said cell produces filamentous bacteriophage.
- 7. The composition of claim 6, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
- 8. The composition of claim 6, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.

- 9. A kit for the preparation of vectors useful for the coexpression of two or more DNA sequences encoding polypeptides which form heteromeric receptors comprising two vectors, a first vector having two pairs of restriction sites symmetrically oriented about a cloning site which can be combined with a second vector, having two pairs of restriction sites symmetrically oriented about a cloning site and in an identical orientation to that of the first vector, wherein one or both vectors contains sequences necessary for expression of polypeptides encoded by DNA sequences inserted in said cloning sites.
  - 10. The kit of claim 9, wherein said first and second vectors are circular.
  - 11. The kit of claim 9, wherein said expression peptides is as fusion proteins on the surface of a cell.
  - 12. The kit of claim 9, wherein said cell produces filamentous bacteriophage.
  - 13. The kit of claim 9, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
  - 14. The kit of claim 13, wherein at least one of the DNA sequences is expressed as a fusion protein with gene VIII.
  - 15. The kit of claim 9, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

- or more DNA sequences encoding polypeptides which form a heteromeric receptor, comprising a set of first vectors having a diverse population of first DNA sequences and a set of second vectors having a diverse population second DNA sequences, said first and second vectors having two pairs of restriction sites symmetrically oriented about a cloning site for containing said first and second populations of DNA sequences so as to allow only the operational combination of vector sequences containing said first and second first and second DNA sequences.
- 17. The cloning system of claim 16, wherein said first and second vectors are circular.
- 18. The cloning system of claim 16, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 19. The cloning system of claim 16, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 20. The cloning system of claim 19, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 21. The cloning system of claim 16, wherein said coexpression of two or more DNA sequences encoding polypeptides which form a heteromeric receptor is on the surface of cell.
- 22. The cloning system of claim 16, wherein said cell produces a filamentous bacteriophage.

- 23. The cloning system of claim 22 wherein said filamentous bacteriophage selected from the group consisting of M13, fd and fl.
- 24. The cloning system of claim 23, wherein at least one of the DNA sequences is expressed as a fusion protein with the protein product of gene VIII.
- 25. The cloning system of claim 16, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.
- 26. A plurality of expression vectors containing a plurality of possible first and second DNA sequences encoding polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said DNA sequence encoding heteromeric receptors being operatively linked to genes encoding surface proteins of a cell.
  - 27. The expression vectors of claim 26, wherein said expression vectors are circular.
- 28. The expression vectors of claim 23, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 29. The expression vectors of claim 26, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 30. The expression vectors of claim 29, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

- 31. The expression vectors of claim 26, wherein said cells produce filamentous bacteriophage.
- 32. The expression vectors of claim 26, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
- 33. The expression vectors of claim 32, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.
- 34. A method of constructing a diverse population of vectors capable of expressing a diverse population of heteromeric receptors, comprising:
  - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
  - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; and
  - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.

10

15

- 35. The method of claim 34, wherein said first and second vectors are circular.
- 36. The method of claim 34, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 37. The method of claim 34, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 38. The method of claim 34, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 39. The method of claim 37, wherein said cell produces a bacteriophage.
- 40. The method of claim 39, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 41. The method of claim 34, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 42. The method of claim 34, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

10

- 43. The method of claim 34, wherein said combining step further comprises:
  - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
  - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites:
  - (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
  - (C4) annealing said first and second vectors.

- 44. A method for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising:
  - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
    - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector:
    - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
    - (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and
    - (e) determining the heteromeric receptors which bind to said preselected molecule.

5

15

20

25

- 45. The method of claim 44, wherein said first and second vectors are circular.
- 46. The method of claim 44, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 47. The method of claim 44, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 48. The method of claim 47, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 49. The method of claim 44, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 50. The method of claim 49, wherein said cell produces a filamentous bacteriophage.
- 51. The method of claim 50, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 52. The method of claim 51, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 53. The method of claim 44, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

- 54. The method of claim 44, wherein said combining step further comprises:
  - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
  - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
  - (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- (C4) annealing said first and second vectors.

10

15

20


25

- 55. A method for determining the nucleic acid sequences encoding a heteromeric receptor exhibiting binding activity toward a preselected molecule from a diverse population of heteromeric receptors, comprising:
  - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
  - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector:
  - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
  - (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences;

- (e) determining the heteromeric receptors which bind to said preselected molecule;
- (f) isolating the nucleic acid sequences encoding said first and second polypeptides; and
- (g) sequencing said nucleic acid sequences.
- 56. The method of claim 55, wherein said first and second vectors are circular.
- 57. The method of claim 55, wherein said first heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 58. The method of claim 55, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 59. The method of claim 58, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 60. The method of claim 55, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell filamentous bacteriophage selected from the group consisting of M13, fd and fl and at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
  - 61. The method of claim 55, wherein said cell produces filamentous bacteriophage.

- 66. A vector comprising two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to a DNA sequence encoding a polypeptide of a heteromeric receptor wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.
  - 67. The vector of claim 66, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.
  - 68. The vector of claim 66, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
  - 69. The vector of claim 66, wherein said bacteriophage coat protein is M13 gene VIII.
  - 70. The vector of claim 66, wherein said vector has substantially the same sequence as that shown in Figure 2 (SEQ ID NO: 1).
- 71. A vector comprising sequences necessary for the coexpression of two or more inserted DNA sequences encoding polypeptides which form heteromeric receptors and two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to one of said two or more inserted DNA sequences wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.
  - 72. The vector of claim 71, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.

- 73. The vector of claim 71, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
- 74. The vector of claim 71, wherein said bacteriophage coat protein is M13 gene VIII.
- 75. The vector of claim 71, wherein said vector has substantially the same sequence as that shown in Figure 6 (SEQ ID NO: 5).



```
10
      20
        30
           46
            i
             50
               - !
                60
```

```
4 / 11

1 ATECTACTA CTATI-GIA AATTGATGCC ACCTITUCIG CTGGGGCC AATGAAATI GO STATEMACTA ATGGTTAA ATGGTTAA
```

555555555566666666666666667777	AATTTAGGT TAGGTTAGGA TGTCTAGGA TGTCTAGGA TGTCTAGGA TGTCTAGGCA CAGCGACAAAAA TGTTAAAAAAA TGTTAAAAAAA TGTTAAAAAAA TGTTAAAAAAA TGTTTAAAAAAA TGTTTAAAAAAA TGTTTAAAAAAA TGTTTAAAAAAA TTTTTAAAAAAAA TTTTCTGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TAACTTAGGACCAACAG TCCGGACCAACAG TCCGGACCAACAG TCCGAACCAACAG TCCAAATTTTCCAAAAAAAAAAAAAAAAAAAAAAAAAA	AT A A COLLAR GOLD CONTROL OF A COLLAR GOLD CO	ATCAGATTATATATATATATATATATATATATATATATAT	ACT TAGE TO TA	TTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTCTAATTTTTT	ACCTAGACTACT TO ACCTAGACT	0.000000000000000000000000000000000000
--------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------

6 / 11

1 AATGCTACTA CTATTACTAG MATIGATEC ACCTTITICAG LICCGECCC AAATGAAAAT 60

21 ATAGCTACTA CTATTACTAG MATIGATEC ACCTTITICAG LICCGECCCC AAATGAAAAT 60

22 ATAGCTACTA CTATTACTAG MATIGATEC ACCTTITICAG LICCGECCCC AAATGAAAAT 60

23 ATAGCTACTA CTATTACTAG MATIGATEC ACCTTITICAG LICCGECCCC AAATGAAAAT 60

24 LICCGAATATT TAAAACATGT TGACCTTACA TGAATGAAACTACACACATTACA CACCATTACA CACC

55941 59061 606181 60623061 60623061 60623061 60621 6066666 6066666 606666 606667 7777 777	GTCAGAGATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA	TTTGATATT TATGATATAGATTCAGATTCAGATATAGATTCAGATATAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTCAGATTTTTTTT	TGAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAATTCAAAAAA	TCACGCGACTACTTACTTCACGCGACCGCACACTTCACTTCACGCGACCGCGACTTCACTTCACGCGACCGCGACTTCACTTCACGCGCCCACACGCGACCGCCACGCGACGCCCCACGCGACGCCCCACGCGACGCGCCCACGCGACGCGCCACGCGCCACGCGCCCACGCGCCCCACGCGCCCCACGCGCCCCACGCGCCCCACGCGCCCCACGCCCCCACGCCCCCC	CCTCGCACACTACACTACACACTACACACTACACACTACACACTACACACTACACTACACTACACTACACACACTACACTACACACACTACACACTACACACACTACACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACACTACACACACACTACACACACTACACACACTACACACACTACACACACTACACACACTACACACACTACACACACTACACACACTACACACACTACACACACACACACACACACACACACACACACACACACAC	3960 3960 4080 4080 4080 4080 4080 4080 4080 40
--------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------	----------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------

181 GTTCCATATT TAAAACATGT TAGGGTTACAG CACCAGATTGAAA CTTCCAGACA CAGCACTAGT TAGAACACTAGT TAGAAACATGT TAGAAAGGAG CACCAGATTCA ACCAGATTAG CTCTAAGCCA CAGCAGTTACTAGT TAGAAACATGT TAGAAAGGAG CACCAGATTCA ACCAGATTAG CTCTAAGCCA CAGCAGTTAGT TAGAAACAGT TAGAAACAGA TAGAATTAGA CTCTAAGCCA CAGCAGTTAGT TAGAAACAGA TAGAATTAGA TAGAACAGAGT TAGAAACAGGA ATATTTGAACAG CAATTAAAACAG TACTTCTAGA CTCTAAACAGA CAGCATTAGAACAGA TAGAATTAGAA CACTACTTTAGA CACTACATTAGACAGA TAGAACACTACTTTTAGAACAGA TATTTAGAACAGA TATTTAGAACAGA TAGAATTATAACAGA TATTTATAGA CAATTCCAGAACACTTTTAGAACAGACTATTTAGAACAGAACACTTTTTAGAACAGAACACTTTTTAGAACAGAACACTTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACTACTTTTAGAACAGAACACACTACAACAGACACACTACAACACACAACACACAACACACAC	284000000000000000000000000000000000000

#### INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/07149 1. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6 According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N-15/64, 15/70U.S.C1.: 435/252.3, 320.1 II FIELDS SEARCHED Minimum Documentation Searched 7 Classification System 1 Classification Sympois 435/69.7. 172.3. 252.3, 320.1 U.S.C1. Documentation Searched other than Minimum Documentation to the Extent that such Occuments are Included in the Fields Searched APS, STN/MEDLINE. TERMS USED: SURFACE EXPRESSION VECTOR#, DIRECTED EVOLUTION. SINGLE CHAIN ANTIBOD?. III. DOCUMENTS CONSIDERED TO BE RE 'ANT . Citation of Document, 15 with inclusion, where appropriate, of the relevant passages 12 Calegory . ! Relevant to Claim No. 13  $\mathbf{Y}$ 40. A. 09/00880 (FOM ST AL) 07 September 1088 see potice dicument. Υ. Mucloso Apido Research. Vol. 12, Ma. 9, 5-75 seemed SEPTEMBER 1984, BOSS ET AL, "Assembly of functional antibodics from immunoglobulin heavy and light chains synthesized in <u>E. coli</u>\*, pages 3731-3806, see the abstract. Y Proceedings of the National Academy of 1 - 75Sciences, Vol. 03, issued AUGUST 1989, SASTRY ET AL, Molining of the immunological repertoire in <u>Ischeriania mili</u> for generation of monoclonal sotalytic antibodies: Construction of a heavy chain variable-region specific cDNA library\*, pages 5708-5700, see the abstract. Y Science, Vol 246, issued 08 December 1989, Huse et al. "Generation of a Large Combinatorial Library of the 1-75 Immunoglobulin Repertoire in Phage Lambda", pages 1275-1281, see entire document. \* Special categories of cited documents; 10 "T" later document published after the international filing date or priority date and not in conflict with the application but document defining the general state of the art which is not considered to be of particular relevance. cited to understand the principle or theory underlying the earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date decument which may throw doubts on priority claim(s) or which is cited to establish the Quolication date of another succider special reason (as specified) INVOIVE BN INVENTIVE STED "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the documen; is combined with one or more other such docuument referring to an oral disclosure, use, exhibition or c 'er means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "4" document member of the same patent family IV. CERTIFICATION

Date of the Actual Completion of the International Search

06 January 1992

International Searching Authority

Date of Mailing of this International Search Report

Signature of Authorized Dicker

ISA YUS